

Analyst

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: M. Beccaria and D. Cabooter, *Analyst*, 2020, DOI: 10.1039/C9AN02145K.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

Current Developments in LC-MS for Pharmaceutical Analysis

Marco Beccaria and Deirdre Cabooter*

KU Leuven, Department for Pharmaceutical and Pharmacological Sciences, Pharmaceutical Analysis,

Herestraat 49, Leuven, Belgium

tel.: (+) 32 (0)16.32.34.42

fax: (+) 32 (0)16.32.34.48

e-mail: deirdre.cabooter@kuleuven.be

Analyst Accepted Manuscript

AbstractView Article Online
DOI: 10.1039/C9AN02145K

Liquid chromatography (LC) based techniques in combination with mass spectrometry (MS) detection have had a large impact on the development of new pharmaceuticals in the past decades. Continuous improvements in mass spectrometry and interface technologies, combined with advanced liquid chromatographic techniques for high-throughput qualitative and quantitative analysis, have resulted in a wider scope of applications in the pharmaceutical field. LC-MS tools are increasingly used to analyze pharmaceuticals across a variety of stages in their discovery and development. These stages include drug discovery, product characterization, metabolism studies (*in vitro* and *in vivo*) and the identification of impurities and degradation products. The increase in LC-MS applications has been enormous, with retention times and molecular weights (and related fragmentation patterns) emerging as crucial analytical features in the drug development process. The goal of this review is to give an overview of the main developments in LC-MS based techniques for the analysis of small pharmaceutical molecules in the last decade and give a perspective on future trends in LC-MS in the pharmaceutical field.

Keywords

Liquid chromatography-mass spectrometry (LC-MS); pharmaceutical analysis; small pharmaceutical molecules; interface technologies; separation techniques

1. Introduction

View Article Online
DOI: 10.1039/C9AN02145K

The process of developing a new drug from first concept to the launch of a commercial product, is long and complex, and can easily take more than a decade and cost over 1 billion Euro. During this process, an intensive search for a drug-like small molecule or biological therapeutic (target) takes place. Once a target has been chosen, the pharmaceutical industry, often with the help of academic centers, uses streamlined early processes to identify compounds with suitable characteristics to make acceptable drugs¹. Genetic, cellular, and *in vivo* tools using animal models are part of the drug discovery preclinical screening process to validate a drug product before testing it as a candidate molecule for clinical development.

The safety of a drug product depends on the toxicological properties of the active substance, and its impurities and degradation products. The quality and quantity of the drug product and the substances used during its manufacturing are typically determined via different analytical methods, such as titrimetric, chromatographic, spectroscopic, and electrochemical methods². Among the chromatographic techniques, liquid chromatography (LC) plays an important role in pharmaceutical industries and analysis. Since its first application in 1980 for the assay of bulk drug materials, LC has become one of the principal methods in both the United States and European Pharmacopoeia³. Due to their high resolving power, LC-based techniques help in the structure determination and quantitation of degradation products and impurities in bulk drug materials and pharmaceutical formulations. In this respect, the choice of the detector is critical to guarantee that all components can be detected. The ultraviolet (UV) detector is still the most commonly used detector in LC. It is capable of monitoring several wavelengths simultaneously by applying a multiple wavelength scanning program. However, it can rarely provide an unambiguous identification.

The addition of further detection capabilities to LC separations offers unique opportunities to support pharmaceutical development efficiently and ensure the quality and safety of pharmaceuticals⁴. The hyphenation of LC and mass spectrometry (MS) has become very important in drug discovery and development due to its high throughput, selectivity and sensitivity⁵⁻⁷. LC-MS combines the separation power of LC (production of pure or nearly pure fractions in a chemical mixture) with the mass analysis capabilities of MS (identification of compounds with high molecular specificity and detection sensitivity). This orthogonal hyphenation provides unique solutions to a wide range of structural characterization problems, resulting in the most powerful analytical tool for non-volatile compounds today⁸. Continuous improvements in LC-MS interface technologies, together with powerful tools for structural analysis have led to a wide range of applications in all stages of drug development (discovery, preclinical and clinical phases), metabolism studies (*in vitro* and *in vivo*), and for the identification of impurities and degradation products⁹.

The aim of this contribution is to give an overview of the main developments in LC-MS for the analysis of small pharmaceutical molecules in the past decade (2010-2019). Among the most important trends, ultra-high performance (UHP) LC, multidimensional (MD) LC, high-throughput LC-MS, as well as various technical aspects, such as miniaturization and microfluidics, new MS interfaces, and their coupling with LC systems are critically examined in the context of pharmaceutical analysis. Strategies to minimize matrix effects and improve sensitivity are briefly discussed. Finally, a short summary of recent applications of LC-MS in the field, such as drug metabolism, drug discovery, chiral impurities, degradation products and pharmacokinetic/pharmacodynamic (PK/PD) studies, is also reported.

2. Recent Developments in LC-MS

View Article Online
DOI: 10.1039/C9AN02145K

2.1. Ionization

The type and the design of the ionization source has an important impact on the performance of an LC-MS method. Electrospray ionization (ESI) is still the preferred ionization method in pharmaceutical analysis for the analysis of thermally labile, nonvolatile and polar compounds^{5-7,10}, followed by atmospheric pressure chemical ionization (APCI) and atmospheric pressure photo-ionization (APPI) for nonpolar or less polar compounds with lower molecular weights¹¹⁻¹³. Since most small molecule drugs are weak bases and hence easily protonated, pharmaceutical analyses are often performed in positive ionization mode. For acidic functional groups that easily lose a proton, negative ionization mode can be applied. Several instruments can nowadays also switch polarity within several tens of milliseconds, making the simultaneous analysis of compounds ionized in different ionization polarity, possible¹⁴⁻¹⁶.

Due to the complementarity of ESI and APCI, the use of multimode ionization sources has been proposed for the LC-MS analysis of samples containing analytes with a wide range in polarity and volatility. Such multimode ionization sources allow the use of ESI and APCI, either individually or simultaneously, in a single analytical run without interruption, hence increasing the analytical throughput. As an example, a multimode ionization source was used in ESI(+), APCI(+) and simultaneous ESI-APCI(+) mode for the LC-MS analysis of nine benzodiazepines and zolpidem¹⁷. It was demonstrated that ESI was more sensitive than APCI resulting in S/N values that were on average 1.7 times higher, while the simultaneous ESI-APCI ionization source was the most sensitive, resulting in S/N values that were on average 2 times higher compared to APCI. These findings suggested a possible additive effect between ions generated by ESI and APCI.

Although APPI is an attractive alternative to ESI and APCI due to its applicability for a broad range of compounds, it is currently not widely used as a result of its limited sensitivity. To enhance the ionization efficiency of the analytes, and improve the sensitivity of the analysis, a dopant is often added to the mobile phase. This, however, makes APPI more complex to use and less generic. In contrast to ESI and APCI, APPI can also be applied in combination with normal-phase conditions wherein flammable mobile-phase solvents are used, since there is no explosion hazard as can be the case with APCI or ESI. In this respect, it has been demonstrated that some of these mobile phase solvents (e.g., hexane-based mobile phases) are self-doping and hence make the addition of dopants redundant¹⁸. In modern commercial APPI sources, ionization and important secondary ion-molecule reactions occur in an open source environment close to the MS sampling orifice. It has been suggested by McCulloch et al. that this open-geometry configuration can strongly influence the ion-molecule chemistry that is crucial for APPI performance, and the efficiency with which ions are transmitted from the source to the MS interface¹⁹. Therefore, the authors suggested to revisit the field-free closed-geometry design that was developed at the same time as the open-geometry configuration. In the closed-geometry design, ion-molecule reactions occur within a closed stainless-steel source block, leading to the formation of analyte ions. When these ions exit the source block, they are transmitted to the MS sampling orifice through a strong electric field that is established between the source block and the MS interface. While transiting through the source block, there is no electric field present ("field-free"), which allows reagent ions and analyte neutrals to travel together for an extended duration¹⁹. The field-free APPI source (FF-APPI) was compared with commercially available open-geometry source designs and yielded a significant sensitivity advantage (5- to 10-fold increase) for the analysis of two neutral steroids. This enhanced sensitivity was attributed to the improved confinement of the ion beam and the increased ion-molecule reaction time in the field-free source. Detection limits obtained with FF-APPI for steroids such as estrone, estradiol and androsterone, were compared to ESI and APCI and were up to 10x lower. Finally, matrix effects were evaluated for complex biological samples, such as human serum, plasma and simulated urine. Matrix effects (ion suppression) in FF-APPI seemed to be enhanced at elevated vaporizer temperatures and at low nebulizer gas pressure, although analyte

1
2
3 sensitivity was improved at reduced nebulizer pressures. Further experiments demonstrated that ion
4 suppression could be almost completely eliminated at high nebulizer pressures (80 psi), however, at
5 the cost of a decreased analyte signal intensity²⁰.
6
7

8 As an alternative to ESI, APCI and APPI, a new atmospheric pressure ionization source, called UniSpray,
9 was recently introduced by Waters Corporation. The UniSpray source consists of a grounded nebulizer
10 spraying onto a high-voltage, stainless steel rod located between the sprayer and the ion inlet orifice
11 of the mass spectrometer. The ionization mechanism of the UniSpray source is similar to ESI, but
12 benefits from additional Coanda and vortex effects to promote droplet break-up and desolvation²¹.
13 The sensitivity of the UniSpray source can be optimized by adjusting the point at which the spray
14 impacts the stainless-steel rod. Maximum source sensitivity is typically obtained when the spray
15 impacts the upper right quadrant of the target, since this leads to the occurrence of asymmetric gas
16 streamlines that are directed towards the ion inlet orifice. The performance of the UniSpray source
17 was compared to ESI on the same MS by direct infusion of a mixture of pharmaceuticals with a variety
18 of physico-chemical properties and indicated similar ionization behavior for both sources, with the
19 formation of the same adducts in similar ratios. When comparing the signal intensity obtained with
20 UniSpray versus ESI for different solvent compositions (percentages of organic modifier and pH) and
21 flow rates, a net gain of 2.2 was generally obtained with the UniSpray source²². When coupled with LC,
22 the UniSpray source demonstrated a slightly improved dynamic range towards lower concentrations.
23 Matrix effects (MEs) were also investigated and compared between UniSpray and ESI for polymer
24 excipients, plasma, bile and urine and were found to be similar for both sources²³. Ciclet and coworkers
25 reported another comparison between UniSpray and ESI coupled with LC in both positive and negative
26 ionization mode in terms of sensitivity, stability, versatility and MEs, using 120 natural compounds
27 covering a broad chemical space. In terms of sensitivity, MS intensities of around 40 natural
28 compounds improved using UniSpray versus ESI, but the benefits of UniSpray ionization strictly
29 depended on the chemical class of the investigated analytes. For some compounds, a 10-fold increase
30 in sensitivity was observed using UniSpray versus ESI, while 23% of the compounds had higher MS
31 signal intensities using ESI. One third of the compounds showed equal sensitivities with ESI and
32 UniSpray ionization²⁴.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 Another recently introduced ionization method is Electrospray Ionization Inlet (ESII), wherein a voltage
54 is applied to a metal union that connects tubing from a solvent delivery system such as an LC pump to
55 a piece of fused silica tubing that is inserted into the heated inlet tube of a mass spectrometer. No
56 nebulizing or desolvation gases are required, while the voltages necessary to obtain maximum
57 sensitivity are typically less than 2.5 kV and hence lower than in ESI. The sensitivity of ESII has been
58 compared to ESI for a number of small molecule drugs on an LTQ Velos mass spectrometer. In ESII, ion
59 abundances of the base peak chromatograms were on average 3-10 times larger than those obtained
60 from the extracted ion chromatograms with ESI for flow rates ranging between 15 and 50 $\mu\text{L}/\text{min}$ ²⁵. In
61 contrast with the Unispray source, the gain in ion abundance was characterized by lower background
62 ions. It should further be noted that ESII performs better at low flow rates, while Unispray is mainly
63 beneficial at higher flow rates.
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

101 All atmospheric pressure ionization techniques suffer from a number of inherent disadvantages such
102 as non-uniform, compound specific responses, limited ionization of non-polar compounds and
103 susceptibility to signal suppression or enhancement, depending on the sample matrix²⁶. The latter
104 phenomenon, also called matrix effects (MEs), can strongly impact the reproducibility, linearity and
105 accuracy of the method, resulting in an unreliable quantitation. MEs in ESI can occur through different
106 processes, such as the competition between matrix components and target analytes for the available
107 charges in the liquid phase. When interfering compounds are present at high concentrations in the
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

matrix, they can also influence the viscosity and surface tension of the droplets that are formed in the ionization interface, hence influencing the transfer of target analytes to the gas phase. Alternatively, analytes can co-precipitate with non-volatile matrix components, which will reduce their capacity to reach the gas phase. Finally, once in the gas phase, the analyte can lose its charge due to neutralization reactions or charge transfer in the presence of interfering compounds²⁷.

In APCI, the analyte molecules are first transferred to the gas phase as a neutral molecule and ionization only occurs in a second step by chemical ionization. This makes that most mechanisms leading to ion suppression in ESI are absent in APCI, resulting in a lower susceptibility to matrix effects. Ion suppression in APCI can still occur, however, for example by the formation of solid precipitates by non-volatile compounds or by the effect of the sample composition on the efficiency of the charge transfer from the corona discharge needle to the analyte. In APPI, ion suppression is probably due to competitive gas-phase ion-molecule reactions. Matrix compounds can either capture the charge from the chemical reagent ion supply or charge can be removed from previously ionized analytes by directly interacting with basic or electrophilic matrix components.

To overcome MEs, the use of electron ionization (EI) MS in combination with LC has been proposed as an alternative to atmospheric pressure ionization techniques. Electron ionization operates via a different ionization mechanism, wherein liquid is completely converted to the gas phase prior to ionization through interaction with an electron beam under high-vacuum conditions. The steps leading to analyte ionization are influenced neither by matrix compounds nor the mobile phase composition. To induce analyte ionization, 70 electron volt (eV) electrons are typically used to transform the analyte into a radical cation. These radical cations undergo single or multiple fragmentations and rearrangements that are well-characterized and predictable. The m/z ratio and intensity of the parent and fragment ions can hence serve as a fingerprint that can be entered in a spectral library for identification against thousands of other library entries obtained under similar conditions. Since the identification potential of library searchable EI spectra, without the drawback of matrix effects, is very interesting for molecules in a liquid phase, several propositions have been made to ionize analytes from a liquid effluent using EI.

In Direct-EI, a low flow rate nano-LC system is coupled to a high vacuum EI source. Nebulization and vaporization of the liquid flow are carried out in the ion source under high-temperature, high-vacuum conditions. An EI ion source is typically made from stainless steel (SS). Adsorption and thermal degradation on the metal surface of the ion source can have a severe impact on the sensitivity and reproducibility of the detection signal, especially for polar, low-volatility and thermally sensitive compounds. It has been demonstrated that ceramic coating of the inner surface of the stainless steel ion source significantly improves the MS signal²⁸. Both for the direct flow injection analysis of 16 polyaromatic hydrocarbons (PAHs) and the Direct-EI-LC-MS analysis of four hormones, peaks obtained with a ceramic coated ion source were much sharper and displayed significantly higher signal-to-noise (S/N) ratios (up to a four-fold increase) compared to a stainless-steel ion source. The application of the Direct-EI LC interface in combination with MS/MS was also demonstrated for the targeted detection and quantification of benzodiazepines in alcoholic drinks²⁹. For this purpose, a fast direct-injection method requiring no prior sample preparation was proposed and validated, resulting in detection limits (LOQ) between 100 and 500 $\mu\text{g/L}$ when injecting 2 μL of sample.

For the untargeted analysis of complex liquid matrices under routine conditions, the group of Cappiello developed another interfacing mechanism for LC-MS based on electron impact (EI), called liquid-EI or LEI³⁰. In LEI, the LC eluate is vaporized inside a vaporization microchannel at atmospheric pressure before entering the ion source (Figure 1a). In this way, solute vaporization occurs near the ion source in an environment that is free of electric potentials. The microchannel, that can be heated to 400°C, is

1
2
3 obtained by lining a standard GC transfer line with a removable fused silica capillary – the liner – to prevent contact between the analytes and the metal surface. A narrower fused silica capillary – the inlet – protrudes the first part of the liner and releases the LC eluate. The eluate will evaporate when it comes into contact with the hot zone of the microchannel. Gas-phase ions that are formed will then move towards the ion source following the pressure gradient between the end of the LC capillary and the high-vacuum zone of the ion source. A helium flow is additionally passed between the inlet capillary and the liner and carries the gas-phase molecules to the ion source. Due to the small size of the microchannel, the residence time of the analytes in the hot zone is minimized, reducing the risk of thermal degradation. This increases the range of applications, especially with respect to nontargeted analyses. LEI ideally works at flow rates between 300 and 800 nL/min and is hence designed to be compatible with nano-LC separations. In order to make the ionization interface compatible with normal bore LC, a flow split needs to be applied post-column.

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The proof-of-principle of the LEI interface was demonstrated for a mixture of 20 environmental priority pollutants with a wide variety in polarity (including caffeine and an estrogen). These compounds can currently not be analyzed at once using commercially available LC-MS equipment. Comparison of the average mass spectra of each compound with an electronic mass spectral library demonstrated that the mass spectrometer, equipped with the LEI interface, was able to generate EI mass spectra with an excellent quality. The applicability of LEI for untargeted analysis was demonstrated by analyzing a brain sample from a victim of sudden infant death syndrome and revealed the presence of benzo[a]pyrene as an environmental toxic contaminant. Recently, the same research group reported some changes in the proposed LEI interface including a modified geometry of the vaporization area. These modifications allow a better control of the heat distribution and an efficient liquid-to-gas conversion³¹.

A disadvantage of Direct EI and LEI is that LC column flow rates are restricted to < 1 μ L/min. This requires the use of nano LC columns, resulting in a lower sample loading capacity and loss in sensitivity. Direct EI-LC-MS and LEI moreover use 70 eV EI which is not always ideal since not all library compounds have a molecular ion³² and LC-MS compounds cannot always be produced with a molecular ion of sufficient abundance, making a correct sample identification ambiguous. In their search for an ionization method that provides library searchable EI fragments in combination with an enhanced molecular ion, Amirav et al. have improved their supersonic molecular beam (SMB) approach for the combination of LC-MS and EI³³. This was done to tackle the poor robustness that was observed for their original system and to extend the useful solvent flow rate range beyond 50 μ L/min.

In the optimized EI-LC-MS with SMB system, the solvent enters via a Z-axis capillary tune device to position the solvent delivery capillary in the spray nozzle (Figure 1b). A Z-axis spray probe tune device allows to adjust the position of the spray nozzle with respect to the entrance of the heated vaporization chamber. A deactivated glass liner that is separately heated and controlled, functions as the heated vaporization chamber. The vaporization chamber is air-cooled at its entrance to prevent the liquid eluents from the LC of forming premature air bubbles that can result in undesirable spray instability. The liquid is pneumatically converted into a spray and the sprayed solvent and sample compounds are fully vaporized. Helium gas is used for nebulization and as a sheath gas, and sweeps the vaporized sample into a separately heated and temperature controlled deactivated fused silica capillary transfer line that separates the high-pressure vaporization chamber and the nozzle. The supersonic nozzle expands the vaporized solvent and sample compounds into a vacuum chamber together with helium gas and make-up gas. This supersonic expansion cools the sample compounds. The expanded jet is subsequently skimmed and collimated in a second vacuum chamber, where an SMB is formed. The SMB contains vibrationally cold sample compounds that pass through a dual cage EI ion source where

the sample compounds are ionized by 70 eV electrons. The formed ions are subsequently introduced into the mass analyzer to record cold-EI mass spectra.

The potential of the EI-LC-MS with SMB system was demonstrated by comparing cold EI mass spectra obtained with the EI-LC-MS with SMB system with their corresponding library EI mass spectra for thermolabile compounds such as sulfamethoxazole and haloperidol. The cold EI mass spectra shared all major fragment ions with the library mass spectra, while the molecular ion was more abundantly present, increasing the confidence level for a correct sample identification. The absence of ion suppression or enhancement effects was demonstrated by spiking a 1 ppm pyrene solution with 1000 ppm each of caffeine and ibuprofen. The flow injection analysis of "pure" and "spiked" pyrene resulted in a similar response for pyrene. This suggests that EI-LC-MS with SMB can be used without prior LC analysis, potentially enabling ultra-fast flow injection analysis.

The applicability of the EI-LC-MS with SMB system was further demonstrated for the fast-isocratic LC-MS analysis of octafluoronaphthalene, pyrene, Agidol 40 and cholesterol and the gradient analysis of dimethylphtalate, diethylphtalate, ethylparaben and butylparaben. These applications demonstrated the potential of EI-LC-MS with SMB for the analysis of relatively non-polar compounds that are hard or impossible to analyze using standard ESI or APCI based LC-MS. Relatively uniform responses were moreover obtained for the different compounds, demonstrating that the ionization efficiency of EI is independent of the compound polarity and identity.

A review on the state-of-the-art in the LC-EI-MS field was recently written by Rigano et al. Benefits and critical aspects were discussed, together with strategies to improve technological hindrances³⁴.

2.2. Mass Analyzers

The types of mass analyzers mainly used in pharmaceutical analysis are ion trap (IT), quadrupole (Q), Orbitrap and time-of-flight (TOF) instruments as well as a variety of hybrid instruments characterized by a high resolution, enhanced sensitivity and/or an increased mass accuracy over a wide dynamic range. Among these, the triple quadrupole (QQQ), quadrupole TOF (Q-TOF), ion trap Orbitrap (IT-Orbitrap) and quadrupole-Orbitrap (Q-Orbitrap)³⁵ are popular.

The performance of a mass analyzer is described by several parameters, such as the resolving power (RP), mass accuracy (MA), mass range (MR), linear dynamic range (LDR), acquisition speed and sensitivity. These parameters need to be carefully evaluated with respect to the final goal of an application. The accuracy of a measurement refers to the degree of conformity between a measured quantity and its true value. MA (in ppm) is usually calculated using the following formula: (measured mass – theoretical mass/theoretical mass) * 10⁶. Internal calibration usually allows to achieve better MA values in comparison with external calibration (2-3 times more) and can be done: (i) by simultaneously introducing a sample and internal calibrant into the ion source by using a splitter tee to introduce the internal calibrant via direct infusion (ii) by using a well-defined ion with known elemental composition originating from the background³⁶, or (iii) by using a microfluid device with two independent ESI emitters to sequentially generate ions from different solutions for mass analysis, using a rapid modulation between ESI emitters. When using external calibration, calibrant and sample are not present in the ion source simultaneously. External calibration can provide similar results to internal calibration if the mass spectrometer is stable enough and does not present any mass drift³⁷ providing the time between the introduction of the sample and the calibrant is as small as possible.

The mass range (MR) is the range of m/z over which a mass spectrometer can detect ions. The acquisition speed is the time the mass spectrometer needs to acquire one spectrum, and is typically expressed in kDa/s for low-resolution and in Hz for high-resolution mass analyzers. Note that numerical

values of acquisition speed in kDa/s and Hz for a specific m/z range are identical. The resolving power (RP) refers to an instrument's ability to distinguish between two adjacent ions of equal intensity and is defined as the m/z value of a peak divided by its peak width, usually measured at full width half maximum (FWHM), indicated as $\Delta m/z$ ($RP = (m/z)/\Delta m/z$). The RP must always be defined for a particular m/z value. Low, high and ultra-high resolution mass analyzers can be distinguished based on the RP, although a clear definition of the ranges is missing³⁷. Low-resolution mass analyzers typically have an RP in the range of 10^3 , while high- and ultra-high resolution MS have an RP in the range of 10^4 - 10^5 and $>10^5$, respectively.

Mass Resolution refers to the ability to separate two neighboring mass spectral peaks and is considered as the minimum mass difference ($m_2 - m_1$) between two mass spectral peaks such that the valley between their sum is a specific fraction of the height of the smaller individual peak. The mass resolution is the inverse of the RP expressed as m/z for a given m/z value. In general, a better mass analyzer will result in lower resolution and higher RP values.

2.2.1 Low Resolution MS

Despite their low resolving power, the development and commercialization of low-cost, small mass spectrometers (mainly quadrupole analyzers) for LC has enabled a widespread use of LC-MS in pharmaceutical applications^{38,39}. Depending on the manufacturer, these mass analyzers are mainly equipped with an ESI source that can operate in positive and negative mode either in sequential runs or within a single run. Mass ranges usually vary between 10 and 1250 m/z , with a mass resolution between 0.5 and 0.7 FWHM^{37,38}. The mass analyzers can be operated in full scan mode or selective ion monitoring (SIM) with scan rates between 3,6 and 10 kDa/s. Depending on the manufacturer, the systems can be operated at flow rates in the $\mu\text{L}/\text{min}$ range (requiring a flow split before entering the MS) and even up to 1 mL/min. Despite some of their disadvantages, such as the limited sensitivity and linear range, these systems are perfectly suited for applications that require less stringent specifications. Examples can be found in reaction monitoring, where the formation of product and the evolution of starting material and intermediates generally only requires unit mass resolution; the high-throughput analysis of microplates that are used to explore a large variety of reaction conditions, and wherein a single quadrupole mass analyzer can usually provide sufficient sensitivity to monitor both starting materials and products, including reaction byproducts (Figure 2). A final example is the identification of compounds, degradation products and impurities to assure the quality of incoming raw materials and active pharmaceutical ingredients (APIs), to perform stability studies and assess metabolization^{40,41}. In this type of studies, the mass analyzer ideally does not only allow quantitation, but can also help in the structure elucidation of the degradation products, impurities and metabolites.

In this perspective, it can be envisaged that these small and cheap mass spectrometers will become more prominent in routine pharmaceutical analyses, and eventually go hand-in-hand with UV detection. In more than 95% of all cases, the quantitation of pharmaceutical compounds is already performed with MS when complex matrices do not allow a reliable spectrophotometric quantification⁸.

2.2.2 High Resolution MS (HRMS)

Although TOF mass analyzers have a lower mass resolution than Fourier transform (FT) mass analyzers (FTICR and Orbitrap), they virtually have no upper m/z limit and are thus particularly useful to identify singly charged ions of high molecular weight. Their fast response/scan rate is also advantageous for applications requiring short acquisition times, e.g., in UPLC- and or LC \times LC-HRMS analysis. Orbitrap and TOF instruments typically produce a mass accuracy of 2–5 ppm. This is sufficient to assign molecular formulae to candidate molecules. It, however, becomes more difficult to identify a compound as the m/z of the ion increases, since more possible elemental compositions will fall within a certain mass

error, making the elemental composition assignment more difficult. Whereas HRMS was originally used in drug metabolism and metabolite identification studies due to its superior qualitative performance, it is nowadays increasingly used to perform reliable and sensitive quantitative analyses⁴². The sensitivity of HRMS is currently often comparable or superior to that of traditional triple quadrupole instruments, due to the possibility to construct extracted ion chromatograms with narrow mass extraction windows. This was for example demonstrated for the analysis of protease inhibitors, tyrosine kinase inhibitors, steroids and metanephrines in plasma samples comparing a new Orbitrap with a recent triple quadrupole⁴³. Similar LOD values were reported for both MS instruments (within a $\leq 2x$ fold difference), whereas the upper limit of quantitation (ULOQ) and curve linearity were better for the Orbitrap (Figure 3).

2.2.3 Tandem MS

MS systems can be used in full-scan mode, providing a complete overview of the sample content (untargeted), or in targeted acquisition modes such as single ion monitoring (SIM) or extracted-ion chromatogram (EIC) mode for a single MS event. To further increase the analytical and identification capabilities of mass spectrometry, tandem mass spectrometry (MS/MS) wherein two stages of mass analysis occur in series to examine the fragmentation behavior of compounds, have found widespread use in pharmaceutical analysis^{44,45}. The principle of MS/MS is that a sample is ionized and analyzed in one stage of mass spectrometry. A particular m/z value is selected from the mass spectrum and directed into a collision cell containing a neutral gas (in general argon, helium or nitrogen). The collision with the gas excites the ion vibrationally, a process known as collision induced dissociation (CID). Other post-source induced fragmentation approaches in the reaction chamber include electron capture and electron transfer dissociation methods (ECD and ETD), surface-induced-dissociation (SID) and photodissociation. The ions (fragments) generated by these processes are separated and recorded in a second stage of mass spectrometry. Mass spectrometers that perform the three steps of the MS/MS process (precursor ion selection, induced dissociation and mass analysis of the product ion(s)) in spatially separated devices, are called "tandem-in-space mass spectrometers", whereas devices that execute the three steps sequentially in the same device are called "tandem-in-time mass spectrometers". Examples of the first type are QQQ and hybrid MS instruments (Q-TOF, IT-TOF, etc), while the second category includes IT, Orbitrap, and FTICR.

Tandem MS can operate in product ion-scanning (PI) mode (MS1 in SIM or EIC mode and MS2 in scan mode); precursor ion-scanning mode (MS1 in scan mode and MS2 in SIM or EIC mode), neutral-loss scanning mode (MS1 and MS2 in scan mode), reaction monitoring mode (MS1 and MS2 in SIM or EIC mode), data-independent acquisition (DIA), and data dependent acquisition (DDA). Reaction monitoring can be executed in multiple reaction monitoring (MRM), selected reaction monitoring (SRM) and parallel reaction monitoring (PRM) mode (Figure 4). PRM is typically executed on a high-resolution hybrid MS instrument, and unlike SRM and MRM, where one or multiple transitions are followed at a time, respectively, PRM monitors all fragments of a precursor ion in parallel⁴⁶. This makes data acquisition methods based on PRM easier to build, since target transitions do not need to be selected in advance.

Product ion and selected reaction monitoring (SRM) scans can be used in the same method with the instrument alternating between the two different scan modes. An example is the LC-MS/MS method proposed by Mazzucchelli et al. for the analysis of doxorubicin and its major metabolite, doxorubicinol, in mouse plasma, urine and tissues. The separation of the analytes was performed in a reversed-phase LC column coupled with ESI-QQQ-MS operated in positive mode. The study was validated according to the US Food & Drug Administration (FDA) guidelines using quality control samples prepared in all matrices⁴⁷.

1
2
3 A common approach for a broad-spectrum drug screening is to perform an SRM scan followed by DDA of PI spectra. In DDA, a fixed number of precursor ions, whose m/z values were recorded in a survey scan in full scan MS, are selected based on predetermined rules and automatically subjected to a second stage of mass selection⁴⁸. DDA allows for specific experimental conditions to be set for the collection of PI spectra of the compound of interest. This method obviates the need to first analyze the sample in full scan mode to identify target precursor ions and then re-analyze the sample in MS/MS mode to acquire MS/MS data for each of the precursors. Not all MS/MS analyzers are capable of performing these scan modes simultaneously in the same method. Recently, Fabresse and coworkers developed and validated an LC-HRMS/MS method showing the potential of DDA in the untargeted identification of new psychoactive substances with the support of available libraries⁴⁹. After the optimization, the method was applied to 11 hair samples, allowing the detection of 284 compounds, of which 72 new psychoactive substances (including a synthetic cannabinoid (AKB48-5F) detected for the first time in hair samples).

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In DIA, all ions within a specific m/z range are fragmented and analyzed in a second stage of tandem MS, in contrast to the sequential detection, selection and analysis of individual ions in DDA. The two most common DIA approaches make use of alternating low/high collision energies (CE) or stepwise isolation windows. The stepwise (or sequential) isolation windows approach leads to an increased specificity, which is particularly useful when analyzing more complex samples. This higher specificity, however, comes at the cost of a decreased duty cycle, depending on the size of the isolation windows and the scanned mass range, ultimately narrowing the mass range that can be sampled. The alternating low/high CE approach on the other hand leads to a higher sensitivity and is mainly limited by the sample complexity.

Examples of alternating low/high CE, in which all precursor ions are fragmented without pre-selection by the quadrupole, are MS^E and All-Ion Fragmentation (AIF). In MS^E platforms, precursor and fragment ion spectra are acquired during a single chromatographic run by alternating low and high CE scans. The low CE allow to obtain accurate mass data for the precursor ions and intensity data for quantification purposes, the high CE allow to obtain accurate masses for the product ions. In All-Ion Fragmentation, fragmentation is obtained with a higher energy collisional dissociation (HCD) cell. After the ions are trapped in the HCD cell, the energy can be increased stepwise at specific percent values around a chosen middle energy value. This is similar to the energy ramping normally employed in MS^E. Noble and coworkers⁵⁰ used DIA in MS^E mode in a targeted screening UHPLC-ESI(+)-QTOF-MS/MS method to identify 50 fentanyl analogues in blood samples without the use of reference standards, under the hypothesis that these compounds with a 4-anilidopiperidine core would follow the same fragmentation pattern as fentanyl. DIA in MS^E mode allowed all precursor ions in the ion source to be analyzed with subsequent fragmentation of the precursors induced by a ramp of CE from 10 to 40 eV, which provided a wider picture of the fragmentation pattern of each compound.

A specific variant of DIA using stepwise isolation windows is called "Sequential Window Acquisition of All Theoretical Mass Spectra" (SWATH-MS), patented by ABSciex. In SWATH-MS, pre-defined ranges of precursor m/z values are successively isolated and fragmented. A single precursor ion (MS1) spectrum is typically recorded, followed by a number of fragment ion (MS2) spectra with wide precursor isolation windows (e.g., 25 m/z). Repeated cycling of consecutive precursor isolation windows over a defined mass range, leads to a comprehensive data set that incorporates continuous information on all detectable precursor and fragment ions. In this way, extracted ion chromatograms can be generated both on MS1 and MS2 level. Arnhard and coworkers⁵¹ compared the qualitative capabilities of DIA (SWATH) and DDA using an LC-ESI-QTOF-MS/MS for a mixture of eight compounds of pharmaceutical interest (bunitrolol, caffeine, cocaine, diazepam, doxepin, haloperidol, 3,4-

1
2
3 methylenedioxyamphetamine and zolpidem) at seven different concentrations (in a range of 1-1000 ng/mL). All 8 standard compounds were positively identified in DIA mode down to 10 ng/mL and 5 out
4
5 of 8 also at 1 ng/mL (lowest level of concentration used), while 5 and 2 out of 8 compounds were
6
7 identified by DDA at the same level of concentrations.

8
9 Although DIA data analysis is more complex than DDA, each acquisition has the potential to provide a
10
11 much more complete picture of the sample and results can improve as libraries are expanded.
12
13 Moreover, in DIA mode, for post-targeting purposes, EICs can be generated on MS2 as well as MS1
14
15 level, while in DDA mode it is only possible on MS1 level (in MRM it is not possible due to the targeted
16
17 data acquisition). A schematic example of MRM, PRM, DDA and DIA is shown in Figure 4⁵².

2.2.4. Quan/Qual analysis

18
19 In drug discovery, major applications are the quantitative analysis of the parent drug and the
20
21 identification of metabolic biotransformation products. Despite the high selectivity and sensitivity of
22
23 QQQ for these purposes, their major drawback is their moderate qualitative capability. Therefore, until
24
25 recently, samples were often analyzed twice: a qualitative analysis by HRMS and a quantitative analysis
26
27 by QQQ. HRMS in full scan mode acquires all ions present in the sample and offers a lot of qualitative
28
29 information. The qualitative performance of HRMS comes from its capability to resolve ions and
30
31 identify unknown molecules. Generally, unknown molecules can be subdivided into known-unknowns
32
33 and unknown-unknowns. The known-unknowns are unknown to the analyst but described in literature
34
35 via MS and MS² spectra, whereas the unknown-unknowns have not yet been identified or reported in
36
37 literature⁵³. HRMS can be used to identify these molecules by the accurate mass of its precursor and
38
39 product ions, providing information on the relative isotopic abundance, the isotopic fine structure and
40
41 ratios between product ions⁵⁴. In combination with the improved quantitative capabilities of the new
42
43 generation of HRMS systems, this has triggered analysts to switch from QQQ systems to HRMS for
44
45 quantitative analysis. In fact, the integration of qualitative and quantitative analysis is of great interest
46
47 in drug discovery, since sample throughput and/or volume can be critical and more high-quality data
48
49 can be needed to improve the drug selection process. On a QQQ, quantitation is usually realized in
50
51 SRM or MRM while in HRMS, the extracted chromatograms are only generated after the acquisition
52
53 and can be simultaneously obtained with the quantitative data.

54
55 According to Kaufman et al., HRMS in full scan mode outperforms QQQ in MRM mode in terms of
56
57 selectivity only if a resolution > 50,000 is achieved⁵⁵. An example of a HRMS Quan/Qual analysis is given
58
59 by the *in vivo* biotransformation study of tamoxifen by Dahmane and coworkers⁵⁶. Plasma samples
60
61 from patients treated with tamoxifen (steady-state levels) were analyzed with an Orbitrap MS
62
63 (Exactive Plus) in HR-full-scan mode. Besides the targeted, quantitative determination of tamoxifen
64
65 and 40 selected metabolites, HR-full-scan mode allowed to identify 39 circulating metabolites of
66
67 tamoxifen, of which 3 were previously not reported. With a similar approach, Rochat and coworkers⁵⁷
68
69 discovered new metabolites of hepcidin by using HR-full-scan acquisition in the context of the
70
71 quantitative determination of hepcidin.

72
73 Narrow mass extraction windows are usually used for the quantitative processing of HRMS data,
74
75 instead of nominal mass product ion chromatograms (SRM or MRM). In this respect, the selection of
76
77 the mass extraction window (MEW) for the construction of the extracted mass chromatogram is
78
79 important. Vereyken and coworkers⁵⁸ investigated the impact of centroid and continuum data on data
80
81 processing in Quan/Qual analysis by using three different HRMS platforms (Waters Q-TOF, Sciex Q-TOF
82
83 and Thermo Orbitrap) coupled to the same UHPLC system. The impact on quantitative HRMS
84
85 performance was evaluated using calibration curves for 8 small molecules (tolbutamide, abiraterone,
86
87 norethindrone, acetaminophen, prednisone, midazolam, loperamide and simeprevir) in plasma using

four different processing softwares (Sciex Analyst[®] TF, Waters Masslynx, Waters Unifi and Thermo Xcalibur). The use of centroid data combined with smaller MEWs provided cleaner EICs, improved the qualitative analyses and reduced the number of false positives in targeted and untargeted analysis. The effect on the quantitative performance was furthermore minimal.

An interesting review on mass spectrometric recommendations for Quan/Qual analysis using LC-QTOF-MS was recently published by Dubbelman and coworkers⁵⁹, while a publication by Sturm et al. discusses the implementation of HRMS analysis on Q Exactive™ series MS instruments in a regulated quantitative bioanalysis environment⁶⁰.

2.3. LC-MS instrumentation

Despite the enormous developments that have been made in mass spectrometry, there are still a number of shortcomings that hamper unlocking its full potential. Firstly, (even high-resolution) mass spectrometry is unable to distinguish isomeric compounds, i.e., compounds with an identical molecular formula but a different molecular structure, that therefore often have a different biological activity. Secondly, the simultaneous introduction of multiple compounds in a mass spectrometer when dealing with complex samples, can seriously influence the ionization efficiency of the compounds of interest. This can lead to an inaccurate quantitation, but also affect the accuracy of the mass measurements. Thirdly, considering an accurate mass measurement at $m/z < 400$, even a mass error of < 1 ppm results in the generation of several potential elemental formulae, and additional tools can be required for an unequivocal identification⁶¹. In order to fully exploit the potential of HRMS, it is hence primordial to combine it with other separation techniques, such as liquid chromatography (LC).

Recent advances to improve the separation performance in LC, such as the development of sub-2 μm fully porous particles (FPPs) and sub-3 μm core-shell or superficially porous particles (SPPs), in combination with instrumentation capable of delivering ultra-high pressures (up to 1500 bar) and with reduced extra-column variances, are increasingly employed in pharmaceutical analysis^{62–64}. Using these novel particle types in combination with UHPLC equipment, pharmaceutical analyses can be performed in less than 10 min, while the time required for method development is also drastically reduced⁶⁵. Analysis time is typically decreased by a factor of 5–9 when a UHPLC column of 50×2.1 mm packed with sub-2 μm particles is used instead of a conventional HPLC column of 150×4.6 mm packed with 5 μm particles, while maintaining column efficiency⁶⁶. Additionally, sub-3 μm SPP packed columns rival the efficiency of sub-2 μm FPP columns for small drugs, while only generating half the backpressure^{67,68}. An evaluation of FPP and SPP columns for the analysis of drugs, including antipsychotics, antidepressants, anticonvulsants and anxiolytics in biological samples by UHPLC-MS/MS was performed in 2017 by the Querioz group. A total of 6 columns (2 FPP and 4 SPP) with different particle sizes were compared in terms of reduced plate height curves, impedance vs reduced velocity, analysis time vs flow rate (mL min^{-1}), backpressure vs flow rate (mL min^{-1}), resolution, peak capacity, asymmetry and retention factor. Overall, the sub-2 μm columns gave the best performance for the analysis of the target drugs in plasma samples⁶⁹.

Hydrophilic interaction liquid chromatography (HILIC) has also known an important revival in the last decade and is nowadays available in a large number of stationary phases and particle designs (including the sub-2 μm FPPs and sub-3 μm SPPs discussed above). HILIC is particularly interesting in combination with mass spectrometry since the high percentage of volatile organic solvent in the mobile phase typically leads to an improved ionization efficiency and increased sensitivity. HILIC is particularly suited for the analysis of polar compounds, and in this respect is increasingly used for the analysis of polar drugs and metabolites^{70,71}.

These new developments in column technology aim at increasing the speed and/or efficiency of the analysis and produce narrow, highly efficient peaks. The hyphenation with mass spectrometry therefore requires state-of-the-art equipment with fast duty cycles, such as QQQ and TOF-MS. Extra-column band broadening should be minimized as well, especially when dealing with narrow-bore and short columns with reduced column volumes⁷²⁻⁷⁴. Since most UHPLC separations are carried out at flow rates between 0.5 and 1.0 mL/min, while the optimum mobile phase flow rate to achieve acceptable ionization yields and sensitivity in ESI is rather between 0.05 and 0.5 mL/min, some technical modifications have been proposed. These include the utilization of additional heated gases to focus the nebulizer spray and improve ion desolvation and modifications to the ion source configuration⁷⁵.

A fast (5 min) UHPLC-UV-ESI(+)-QTOF-MS method using a C18 sub-2 μm FPP column was developed and validated by Schreiber and coworkers for the separation and determination of tadalafil (a drug used for erectile dysfunction) and its impurities in pharmaceutical samples. The proposed method was validated according to the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use in terms of accuracy, selectivity/specificity, linearity and robustness⁷⁶. A UHPLC-MS/MS method for the simultaneous determination of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma using a short C18 50 \times 2.1 mm sub-2 μm FPP column coupled to an ESI(+)-QQQ-MS operating in MRM mode was developed and applied by Wang and coworkers. After liquid-liquid extraction of the plasma samples, analytes were characterized in less than 2 min and the method was validated for accuracy, precision, matrix effects and linearity⁷⁷. Rakuša and coworkers used a short C18 50 \times 2.1 mm sub-3 μm SPP coupled to an ESI(+)-QQQ-MS operating in MRM mode for the fast analysis of rifampicin in human plasma after protein precipitation and solid-phase extraction. The total run time including re-equilibration was 2.4 min. After the optimization and validation according to EMA guidelines, the method was used to quantify rifampicin in plasma samples of 340 patients, demonstrating that it is suitable both for therapeutic drug monitoring and pharmacokinetic analysis⁷⁸. Core-shell technology was also employed for the separation of total and free daptomycin (antibiotic drug) in human plasma. Free daptomycin in plasma was obtained by centrifugal ultrafiltration. Deproteinized plasma samples were directly separated on a C18 150 \times 2.1 mm sub-3 μm SPP column under isocratic elution conditions in 10 min. The RPLC column was coupled with an ESI(+)-QQQ-MS operating in MRM mode for detection and quantification⁷⁹.

For complex samples, containing a mixture of compounds with a large variety in physicochemical properties (e.g., containing both very polar and very apolar compounds), even the most efficient columns can often not resolve all important peaks in the chromatogram^{80,81}. In this case, two-dimensional liquid chromatography (2D-LC) techniques can be employed to increase the separation capacity. Since commercially available 2D-LC systems have recently entered the market^{82,83}, 2D-LC approaches are nowadays also increasingly employed in pharmaceutical analysis.

Two-dimensional separations are predominantly performed in heart-cutting (LC-LC) or comprehensive (LC \times LC) mode⁸⁴. In heart-cutting mode, the effluent of a first-dimension separation is only collected in a region of particular interest (e.g., where compounds are co-eluting) and re-injected on a second-dimension column for further separation. Typical applications of heart-cutting 2D-LC in pharmaceutical analysis involve the isolation of impurities from the active pharmaceutical ingredient (API) or an interfering matrix in the first dimension, the combination of achiral and chiral columns for the separation of enantiomers in the second dimension, and online desalting of peaks eluting in MS-incompatible mobile phases in the first dimension^{83,85-87}.

1
2
3 Online heart-cutting 2D-LC was for example applied to identify an unknown impurity that was formed
4 when an API was stored in an IV delivery device in the presence of polyethylene glycol (PEG)⁸⁵. This
5 impurity co-eluted with PEG, but could clearly be detected in UV due to the lack of UV-absorbance of
6 PEG. In MS, however, it was completely obscured by PEG oligomer peaks, making identification of the
7 impurity impossible even when using high-resolution Orbitrap MS. Online 2D-LC/MS was therefore
8 applied to separate the impurity from the PEG matrix. Both first- and second-dimension separations
9 were done on C18 columns. The first-dimension separation was carried out on a FPP 5 μm column
10 employing mobile phases consisting of trifluoroacetic acid (TFA) in water and acetonitrile. The second-
11 dimension separation was carried out on a SPP 2.7 μm column and employed formic acid in water and
12 acetonitrile as mobile phases. These conditions were selective enough to separate the impurity peak
13 from the PEG matrix to gain sufficient MS abundance for structure elucidation. Another application of
14 online heart-cutting 2D-LC-MS involved the combination of achiral and chiral columns to evaluate the
15 brain response of a chiral compound in rat brain microdialysates⁸⁶. The achiral column was used to
16 evaluate the metabolization of the chiral compound (by separating its main metabolites) and its
17 biological activity (by separating the neurotransmitters dopamine, acetylcholine and 5-
18 hydroxytryptamine). The chiral compound itself, which eluted last from the achiral column, was heart-
19 cut and transferred to a chiral column to measure the brain concentration of the single enantiomers
20 in order to investigate potential stereoselective adsorption or preferential metabolism of one of the
21 enantiomers.
22
23
24
25
26

27 Many pharmaceutical analyses still require mobile phases that are incompatible with MS (containing
28 ion-pairing reagents or non-volatile salts) to separate the API from its impurities. 5-aminolevulinic acid
29 (ALA) for example, is a very hydrophilic compound that cannot be retained or separated from its
30 impurities under standard reversed-phase conditions. The addition of ion-pairing reagents to the
31 mobile phase leads to sufficient retention of all compounds but makes the method incompatible with
32 MS, which is essential for the identification of unknown impurities. Therefore, an online heart-cutting
33 method was proposed wherein ALA and its impurities were first separated on a C18 column using a
34 mixture of sodium octanesulfonate/potassium dihydrogenphosphate/acetonitrile as the mobile
35 phase⁸⁸. Each impurity and the main compound were subsequently trapped individually in a trap
36 column (each time requiring a separate injection) and transferred to the second-dimension column,
37 which consisted of a C8 column and was operated using a mobile phase consisting of water, acetic acid
38 and acetonitrile. The eluent of the C8 column was finally eluted to an ESI-MS/MS system for structure
39 elucidation. By diverting the eluents of the C8 column to the waste for the first minute of the analysis,
40 contamination of the MS by non-volatile salts was avoided and ion suppression significantly reduced.
41
42
43
44

45 Online heart-cutting generally only allows the analysis of a very limited number of fractions eluting
46 from the first-dimension column, since a new fraction can only be analyzed once the previous fraction
47 has been separated on the second-dimension column. As demonstrated by the previous example, this
48 might require the same sample to be injected multiple times, each time fractionating another impurity.
49 One way around this is to apply multiple heart-cutting 2D-LC. In this approach, a multitude of heart-
50 cuts from the first dimension separation are sampled into multiple loops or trap columns, where they
51 remain parked until they are analyzed on the second dimension column⁸². By parking the fractions
52 eluting from the first-dimension separation in this way, the timescales applied in the first and second
53 dimension are disconnected. This allows optimizing the separation conditions in both dimensions
54 independent of each other to obtain the maximum possible resolution in both dimensions. Since
55 multiple fractions can be taken from the first-dimension separation at once, the time required to
56 identify all impurities in a sample is significantly reduced compared to "single" heart-cutting 2D-LC.
57
58
59
60

Multiple heart-cutting 2D-LC was for example applied to characterize eight impurities in cefpiramide⁸⁹. For this purpose, cefpiramide was first separated from its impurities using the non-volatile mobile phase conditions prescribed by the US Pharmacopoeia in the first dimension. Each peak separated on the first-dimension column was subsequently trapped into a separate 20 μ L loop and transferred to a second-dimension column once the first-dimension separation was complete. Employing a volatile mobile phase for the second-dimension analyses, the peaks could be eluted towards an IT-TOF-MS equipped with ESI interface for detection and structure elucidation. In 2019, the same research group applied a similar multiple heart-cutting 2D-LC-ESI-IT-TOF-MS method for the separation and characterization of new components and impurities in leucomycin⁹⁰. A non-volatile buffer solution was used as the mobile phase in the first-dimension, modifying the gradient of the non-volatile mobile phase method reported in the Chinese and Japanese Pharmacopoeia for leucomycin to improve the separation. Peaks eluting from the first-dimension were trapped using a switching valve and sent to the second-dimension column and then to the MS system using a volatile mobile phase consisting of methanol and ammonium acetate for the second-dimension. Six impurities were previously not reported. Four of these impurities were acid degradation products, while the other two impurities were process impurities.

Another particular form of heart-cutting was proposed to increase the sensitivity of the analysis of midazolam and 1'-hydroxymidazolam in plasma⁹¹. For this purpose, 80 μ L of protein precipitated plasma was first injected on a 2.1 mm I.D. trapping column. The trapping column was subsequently switched in-line with a 1.0 mm I.D. UHPLC column to separate the sample. When the analytes of interest eluted, the 1.0 mm I.D. column was switched in-line with a second trap column with an I.D. of 0.5 mm to trap the heart-cut. Finally, the second trap column was back-flushed onto a chip-based column with an I.D. of 0.15 mm and an orthogonal separation was performed. By gradually decreasing the column diameter along the flow path, the high sampling efficiency (i.e., efficiency of ion creation x ion transfer from atmosphere to vacuum) obtained when coupling a low I.D. column operated at a low flow rate with an ESI-MS, could be combined with the high sample loading capacity of a large I.D. column. This resulted in an increase in sensitivity that was 250-500 x higher compared to direct injection of 0.2 μ L of the same sample on the chip-based column, and 10-50 x higher compared to injecting 10 μ L of the same sample on the chip-based column after trapping on a trap column.

Another 2D-LC application was proposed by Yu et al. using an LC-LC-ESI-QQQ-MS/MS method for the determination of tramadol and its phase I and II metabolites in hair. After extraction from hair, drugs were analyzed using a HILIC column in the first dimension for class separation and a RPLC column in the second dimension for intra-class separation. Identification and quantification of the analytes was done in selected reaction monitoring (SRM) mode. The method was validated in terms of LOD, LOQ, accuracy, sensitivity, and matrix effects⁹².

In comprehensive 2D-LC (LC \times LC), the entire effluent eluting from the first-dimension column is fractionated and transferred to the second-dimension column for further separation. By applying a very short sampling time (modulation time, usually less than 2 min), each peak eluting from the first dimension is sampled at least three or four times. This generally requires a very slow first dimension separation in combination with a very fast second dimension separation to avoid losing the resolution obtained in the first dimension. LC \times LC leads to very powerful separations, but also to complex data since every compound is cut into multiple peaks. Choosing the two separation dimensions can be critical and is not straightforward. Particular attention should be paid to the complementarity of the stationary phases, the miscibility of the mobile phases used in the first and second dimension and the impact of the injection of the first-dimension mobile phase on the separation in the second dimension. A comprehensive overview about possible combinations in retention mechanisms (selectivities) in

1
2
3 LC×LC has recently been given by Pirok et al., evaluating potential peak capacities, column re-equilibration times and other critical requirements mentioned above⁹³. Since comprehensive 2D-LC provides a global perspective on the sample, it is often used for very complex samples typically encountered in proteomics, metabolomics, biopharmaceutical analysis and natural products^{94–96}.
4
5
6
7
8

9 Examples of comprehensive 2D-LC in combination with MS for pharmaceutical analysis were recently given by Heinisch et al.^{97,98}. In their studies, the authors defined generic 2D-LC systems that can be used to improve the knowledge on impurities during drug development significantly. For this purpose, the degree of orthogonality and the practical peak capacity of 190 RPLC x RPLC configurations was first assessed for two real pharmaceutical samples⁹⁷. Out of these 190 combinations, three RPLC x RPLC configurations with the same second dimension were selected that provided i) a very high peak capacity for the first configuration, ii) a sufficient degree of orthogonality between the first and second dimension for the other two configurations, iii) a second-dimension column capable of withstanding high temperatures and iv) second dimension conditions that were MS compatible. These three configurations were hyphenated to a UV and a single quad MS to identify impurities in two pharmaceutical samples. Figure 5 shows the utility of MS to identify impurities by comparing the second-dimension chromatograms obtained with UV (Fig. 3a) and MS (Fig. 3b) for the pharmaceutical samples. Two compounds (indicated in red in Fig. 3b) were only detected with MS. For all three configurations, peak capacities close to 900 were obtained in less than 50 min, while most impurities could be detected with each of the three configurations. While the use of one LC×LC – UV/MS system outperformed the number of compounds detected by one 1D-LC-UV/MS system with 40%, the addition of a second and a third LC×LC – UV/MS system further increased this number by 12% and 3%, respectively. These findings suggest that a limited number of well-chosen combinations of LC systems can be sufficient to characterize any pharmaceutical sample. In 2019, the same research group assessed the quantitative performance of an online RPLC x RPLC system for pharmaceutical analysis, taking into account the low quantitation and detection limits required by ICH guidelines⁹⁸. An in-house developed procedure, using predictive calculation tools and a Pareto optimization approach, was used to optimize the RPLC x RPLC conditions. Similar to the previous publication, two sets of conditions were selected: one favoring a high effective peak capacity and one favoring a low dilution factor (Set-up #1 and Set-up #2, respectively). The optimized RPLC x RPLC separations resulted in peak intensities that were 3-4 fold higher with Set-up #2 in comparison with Set-up #1 for low level impurities. Set-up #2 allowed to detect impurities with LOQs between 0.05% and 0.1% of the API. The optimized conditions were then applied to analyze a real pharmaceutical sample. Impurities present at concentrations as low as 0.04% of the API were detected with S/N ratios above 3, whereas impurities at concentrations of 0.1% of the API were detected with S/N ratios above 10. A recent overview of studies and emerging trends in online 2D-LC techniques applied to pharmaceutical compounds, covering the late 1980s to 2017, is given by Iguiniz & Heinisch⁹⁹.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 2.4. Miniaturization and Microfluidics

49
50 Capillary and nano-scale LC in combination with MS have the ability to address small sample sizes and provide high sensitivity information, which is particularly interesting when dealing with small sample volumes and low abundant compounds. When column dimensions are moreover reduced to 100 μm or less, there is no need for a nebulizer gas, as long as the mobile phase contains a reasonable concentration of organic modifier (15-20%)¹⁰⁰. Originally, capillary and nano-scale LC were mainly used in proteomics, since in drug development, drug metabolism and pharmacokinetic (DMPK) studies, there is rarely a limitation in sample volume. The high level of sensitivity achievable with capillary and nano-scale LC can, however, also be useful in pharmaceutical applications, for example to create an entire pharmacokinetic (PK) profile from a single animal, since only small sample volumes are
51
52
53
54
55
56
57
58
59
60

1
2
3 required¹⁰¹. The analytical method should, however, be sufficiently robust to ensure the entire batch
4 of samples can be analyzed using the same set-up. The extra sensitivity of capillary scale separations
5 can also be used to identify metabolites in very early *in vivo* pharmacodynamics studies requiring only
6 minimal amounts of the candidate drug. This allows the compound to be fully evaluated without
7 needing larger scale synthesis¹⁰².
8
9

10 Capillary and nano-scale separations, however, also have a number of drawbacks. Due to the small
11 column volumes and difficulty of making dispersion-free connections, extra-column band broadening
12 is more of an issue than in normal bore separations. The small ID columns and tubings are more prone
13 to blockage, especially when dealing with “dirty” samples. And thirdly, there is a need for MS sources
14 that can effectively work with LC flows in the nL- μ L range. To overcome some of these issues, fully
15 integrated microfluidic devices or chips have been developed. These devices commonly combine an
16 open tubular LC column with reduced column ID with improved spray/tip connections for hyphenation
17 with MS. A recent study comparing four emitter geometries for the hyphenation of LC microchips to
18 MS demonstrated that at flow rates down to 15 nL/min, a perfectly three-dimensional sharp (“pulled”)
19 emitter tip performed best. However, at flow rates above 50 nL/min, less sharp (ground pyramidal
20 shaped) or corner cut and even blunt emitters performed equally well¹⁰³. Schematic drawings and SEM
21 images of these emitter geometries can be found in Figure 6. These findings indicate that elaborate
22 techniques to sharpen or ground electrospray emitter tips are less critical in chip-based LC-MS
23 operations, compared to low flow rate techniques such as chip electrophoresis.
24
25
26

27 Microchips furthermore can also incorporate other components, such as trap or enrichment columns
28 and valves. By combining multiple components on a single chip, void volumes are drastically reduced.
29 Challenges that remain are the limited loading capacity, that can however at least partially be relieved
30 by a pre-concentration step, and potential clogging problems.
31
32

33 The potential of a capillary scale (300 μ m ID) ceramic microfluidic LC device in combination with
34 MS/MS for DMPK studies employing low-volume biological samples has been demonstrated by
35 Nicholson *et al*¹⁰⁴. In comparison with a standard 2.1 mm ID UHPLC column, the capillary ceramic
36 microfluidic column resulted in an 11- to 38-fold increase in sensitivity for a broad range of
37 pharmaceuticals when employing the same triple quadrupole mass spectrometer and an identical
38 injection volume of 1 μ L. This is slightly lower than the theoretically expected increase of 49, but
39 nevertheless demonstrates the potential of the microfluidic device for the analysis of pharmaceuticals
40 in small sample volumes, such as those obtained from dried blood spots or other blood microsampling
41 techniques. The loading capacity of the ceramic microfluidic device was also investigated and it was
42 demonstrated that, in combination with a reversed-phase gradient, an aqueous solution of the
43 antidepressant alprazolam with a volume up to 2 μ L could be injected onto the column without
44 negatively affecting the chromatographic performance. For a biological sample spiked with alprazolam
45 and submitted to protein precipitation and therefore contained in a large percentage of acetonitrile (~
46 60%), the maximum injection volume was 1.2 μ L. Note that these results are very analyte dependent
47 (depending on the retention on the analyte) and will also depend on the length of the column and the
48 injection mode. The robustness of the ceramic microfluidic LC-MS system towards the injection of
49 plasma-derived samples was demonstrated for 1000 sample analyses, while the intercolumn
50 performance of six different microfluidic devices was demonstrated in terms of reproducibility and
51 column efficiency.
52
53
54
55

56 Several companies (Agilent Technologies, Eksigent, Waters) have meanwhile commercialized
57 miniaturized LC systems with integrated LC microchips for chip-based LC-MS analysis¹⁰⁵. Depending on
58 the manufacturer, these microchips are available in different channel lengths (up to 150 mm), particle
59 sizes (ranging between sub-2 μ m, 3 or 5 μ m fully porous, and 2.7 μ m superficially porous particles) and
60

stationary phases (C18, C8, graphitized carbon and HILIC). Steuer and coworkers compared a conventional LC-MS/MS set-up with an Eksigent microflow (MF) LC-MS/MS for the simultaneous quantification of 40 antidepressants and neuroleptics in whole blood within the framework of full method validation. LC analyses were carried out on a Polar RP 2.5 μm FPP column (100 x 2.0 mm) connected with a linear ion trap quadrupole mass spectrometer (ABSciex 5500 QTrap), while MFLC analyses were performed on a 2.7 μm Phenyl-Hexyl SPP micro-column (50 x 0.5 mm) connected with a linear ITQ-MS equipped with an ESI interface (ABSciex 4500 QTrap). Both mass spectrometers have the same geometry, ion source and scan speed, but the 5500 system has a larger ion inlet diameter, leading to a slightly higher sensitivity. It should furthermore be noted that different gradient profiles and injection volumes were used on both columns (10 μL on the conventional column and 5 μL on the MFLC). The authors demonstrated a dramatically lower solvent consumption for the MFLC system, and an improved peak separation (no further explanation was however provided for the choice in gradient profile on each of the chromatographic systems, or how these gradient profiles were obtained). In terms of peak interferences, LOD, MEs and precision, the systems were shown to perform comparably under the applied conditions. Advantages of the LC system were the linear calibration models and more stable retention times, leading to a higher robustness, while the system was also easier to maintain in terms of column care and column life time¹⁰⁶.

The Agilent Chip Cube was used in combination with a Q-TOF MS to examine the composition of Ukrain, a drug used for the treatment of different types of cancer¹⁰⁷. Ukrain is a semi-synthetic alkaloid derivative of *Chelidonium majus*, a medicinal plant of the *Papaveraceae* family. To unravel the composition of Ukrain, TLC, semi-preparative TLC and Chip Cube LC-MS/MS experiments were conducted on Ukrain samples and compared with an alkaloid extract of *C. majus* roots. It was demonstrated that Ukrain contains a mixture of alkaloids. Some of them, such as stylophine, norchelidonine and hydroberberine, were reported for the first time.

The Chip Cube was hyphenated with ICP-MS for the analysis of cyanocobalamin in equine plasma as a means to distinguish inorganic cobalt and cobalamin in doping investigations¹⁰⁸. The use of a nano LC flow allowed to reduce the organic solvent load introduced into the ICP-MS, reducing signal suppression. To hyphenate the Chip Cube to ICP-MS, the electrospray tip was removed and the eluent diverted to an unused stator port in the chip, prior to introduction into the nebulizer. The nebulizer was modified to reduce post-column band broadening, while the spray chamber was adapted to introduce a make-up gas flow at an angle perpendicular to the nebulizer flow. This prevented the nebulized eluent from depositing on the spray chamber walls, since no carbon deposition on the cones or baseline drift was observed during six weeks of operation. The developed method displayed good linearity of 0.9999 between 10 and 1000 ng/mL and a limit of detection of 14 ng/mL (corresponding with 0.57 ng/mL Co).

Houbart et al. reported a chip-based LC MS/MS method for the quantification of fluoxetine and its metabolite (norfluoxetine) in serum samples of rat. A 20 μL serum sample was vortexed, centrifuged and then subjected to SPE before the chip-based LC-MS analysis. Linearity was obtained in the range of 25–500 ng/mL for both compounds. The LODs of fluoxetine and norfluoxetine were 0.18 ng/mL and 0.67 ng/mL, respectively. The precision (RSD) of the LC-MS/MS method was 3.0–13.3% and 6.4–16.5% for fluoxetine and norfluoxetine, respectively¹⁰⁹.

LC chip MS systems are expected to have more widespread applications in the pharmaceutical field in the near future. From a high-throughput point-of-view, chip-size LC-MS devices can lead to a reduction of the total analysis time, increasing the number of possible runs per day. Alternatively, these devices may in the future be used in applications such as tissue engineering and organ-on-chip platforms to monitor cells and tissues in real-time during their development and in response to drugs¹¹⁰.

2.5. Matrix Effects

View Article Online
DOI: 10.1039/C9AN02145K

Despite the high specificity of LC-MS techniques for drug analysis, an adequate sample preparation step to isolate the drug and its metabolites from the matrix remains necessary in many cases. An ineffective separation can result from interactions between sample impurities and the stationary phase, increasing the noise level at the detector; interaction of the drug of interest with other matrix components and poor resolution. All these shortcomings lead to so-called matrix effects (MEs), that severely limit quantitative analysis and affect the reproducibility, linearity, and accuracy of the methods. MEs can be regarded as an increase (ion enhancement) or loss (ion suppression) in response and are often caused by an altered ionization efficiency of compounds of interest due to co-eluting analytes in the same matrix¹¹¹.

Different strategies can be applied to minimize MEs, such as different sample preparation approaches, dedicated chromatographic techniques, the application of appropriate calibration methods, and the choice of the correct ionization source before the MS detection. Widespread pretreatment methods in the pharmaceutical field are solid phase extraction (SPE) and liquid-liquid extraction (LLE), while supported liquid extraction (SLE) and solid-phase microextraction (SMPE) are also more and more commonly applied. Several studies demonstrate that a major contribution to MEs in biological fluids can be ascribed to glycerophosphocholine (GPCho) lipids due to their surfactant-like properties^{112,113}. Yan and co-workers used a LLE method based on ethyl acetate to remove glycerophosphocholines from biological samples for the determination of ropinirole in rat, eliminating the matrix effect¹¹⁴. Koller and coworkers used a phospholipid-removal microelution-solid phase extraction method (μ SPE) to eliminate the matrix effect in human plasma samples for the simultaneous determination of aripiprazole, its metabolite dehydro-aripiprazole, olanzapine, risperidone, paliperidone, quetiapine, clozapine and caffeine¹¹⁵.

SPE has several advantages compared to LLE techniques. It can be easily automated, and can be performed on-line in combination with LC. A wide range of SPE sorbents are available and a large number of protocols can be conceived to selectively purify the compound of interest from interferences. Such sorbents include surfactant-modified sorbents, mixed-mode polymeric sorbents, molecular recognition sorbents (immunosorbents, molecularly-imprinted sorbents, aptamers) and nanostructure materials (carbon nanotubes, electrospun nanofibers)¹¹⁶. Different approaches exist to automate both off-line and on-line SPE. Precisions are usually similar for both techniques, whereas recoveries for SPE are in general better than those for LLE¹¹⁷. An example of off-line and on-line SPE-LC-MS/MS was reported by Soichot et al., for the detection of opioids in human urine samples. Analyses were carried out in urine samples by offline SPE followed by an LC-MS targeted screening for common opiates. The concentrations of morphine and codeine were also determined in plasma samples using automated online SPE-LC-MS/MS. The separation of the analytes and the internal standard was carried out using an RPLC column and detection was done using ESI(+)-QQQ-MS in MRM mode. The method was validated for specificity, accuracy, precision, stability, linearity, carry-over, matrix effects and recovery according to the European Medicines Agency (EMA) guidelines¹¹⁸.

Improving the chromatographic separation can also help to overcome MEs, by separating the compounds of interest from the matrix to avoid mutual interactions and competitions. Different stationary phases, mobile phases and gradient conditions can be applied to change the retention times of components in a complex mixture. As discussed in Section 2.3, several recent column and separation strategies allow achieving a better resolution and reduce MEs. Finally, also the MS conditions can be changed to reduce MEs. It is well known that the intensity of MEs depends on the ionization technique applied, the source design or positive/negative ion acquisition. Among the various API techniques, ESI is more sensitive to MEs than APCI, while APPI is the least sensitive²⁷.

Besides the aforementioned strategies to limited MEs, a suitable calibration technique is also indispensable to compensate for changes in signal. The standard addition method is probably the most effective way to compensate for MEs on the method performance¹¹⁹. However, this approach is laborious and time-consuming¹²⁰. The external standard calibration method is not appropriate if standards are spiked in a solvent instead of in the matrix, since MEs will not be adequately accounted for in a solvent. The most effective calibration approach to minimize MEs is through the use of a structural or stable isotope labelled (SIL) internal standard (IS), where the analyte of interest and the IS should undergo the same procedure(s). Recently, Whang and coworkers developed a multi-matrix LC-MS/MS method for the determination of urea in plasma in the context of human respiratory diseases¹²¹. Two stable-isotope-labelled urea isotopologues, [¹⁵N₂]-urea and [¹³C,¹⁵N₂]-urea, were used as the surrogate analyte and the internal standard, respectively, providing the best measurement consistency across different matrices. An alternative approach is the use of stable isotope labelled reagent molecules to derivatize compounds of interest (for example to make them more ionizable under ESI-MS) for differential analysis in two comparative groups of samples (e.g., patients under drug treatment and a control group). This approach is called stable isotope-coded derivatization (ICD) and has been used as a method to correct for run-to-run ionization differences, including matrix effects¹²². Higashi et al. developed a LC-ESI-QQQ-MS/MS method for a differential analysis and quantification of allopregnanolone and its precursor pregnenolone (neuro-steroids) in brain rat after converting them to highly detectable derivatives using 2-hydrazino-1-methylpyridine (HMP) and its isotope-coded reagent (²H₃-HMP (*d*-HMP))¹²³.

2.6. Ion mobility mass spectrometry

The principle of ion mobility is based on the drag force the ions of interest experience when moving through an electrical field in a drift cell, while at the same time undergoing collisions with stationary buffer gas molecules (typically nitrogen or helium gas) in the cell. Different forms of ion mobility based on this principle exist, such as Drift-Tube ion mobility (DT-IM), Travelling-Wave ion mobility (TW-IM) and Trapped ion mobility (TIM), and are currently available in integrated commercial LC-MS instruments³⁷. In DT-IM, for example, the ions move in a linear drift tube through a homogeneous, continuous electric field filled with a neutral gas. The combination of acceleration due to the electric field and deceleration due to collisions with the gas leads to a state of equilibrium wherein the molecules move at a constant velocity. This velocity depends on the applied electric field and structural characteristics of the molecules, such as size, shape, electrical charge and mass (their collision cross section or CCS). In this way, IM allows separating isomers, isobars, and conformers, reducing chemical noise and measuring ion sizes. Additionally, ions of the same charge state and structurally similar ions can be separated in ion families which appear along a unique mass-mobility correlation line¹²⁴.

The main field of application of LC-IM-MS is the analysis of complex samples such as in proteomics and metabolomics and only few applications have been developed in the context of small molecules in pharmaceutical analysis. Recently, Hernández-Mesa and coworkers characterized phase II steroid metabolites (*i.e.*, androgen and estrogen conjugates, including glucuronide and sulfate compounds) in urine samples using an LC-IM-TOF-MS system. It was observed that the S/N ratio improved 2-7 fold when IM was combined with LC-MS. Besides separating isomeric steroid pairs (etiocholanolone glucuronide and epiandrosterone glucuronide, 19-noretiocholanolone glucuronide and 19-norandrosterone glucuronide), the IM dimension also allowed to separate steroid-based ions from co-eluting matrix compounds with similar *m/z* ratios¹²⁵.

The addition of IM to LC-MS workflows in pharmaceutical analysis can also bring an improved spectral quality to DIA modes by filtering MS and MS/MS data according to drift time in addition to retention time, by the increased duty cycle, by separating ions of different charge states and the potential to

1
2
3 separate isomeric and isobaric compounds. Experimentally determined CCS values can moreover be
4 used to obtain conformational information about the compound of interest and can be used as an
5 additional identification parameter. View Article Online
DOI: 10.1039/C9AN02145K

3. Applications of LC-MS in Pharmaceutical Analysis

3.1. Drug Metabolism Studies

6
7
8
9
10
11 At the discovery stage, it is not only necessary to qualitatively identify metabolites in *in vitro* and *in vivo*
12 studies, but it is also important to quantitatively estimate the importance of each metabolite so
13 that metabolic liabilities can be addressed during compound optimization. This means that major
14 pharmacologically active metabolites must be identified and if necessary monitored in discovery and
15 investigational new drug-enabling toxicological studies. Early phase metabolism studies typically rely
16 on the use of LC-MS to analyze samples derived from *in vitro* incubations (e.g. with liver microsomes
17 or hepatocytes) and/or *in vivo* studies. LC-MS allows the rapid identification and partial structural
18 characterization of metabolites, with a high sensitivity for most drug candidates and metabolites¹²⁶.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
216

1
2
3 “MISER” (Multiple Injections in a Single Experimental Run) chromatography. Currently, several
4 manufacturers offer staggered systems, such as MPX (Sciex), Transcend II (Thermo) and StreamSelect
5 (Agilent). Since chromatographic separations in the sub-5 s range can nowadays be carried out, faster
6 autosamplers are needed to further improve the speed of analysis in high-throughput LC–MS analysis.
7 Zawatzky and co-workers developed a dual needle autosampler increasing the throughput of MISER
8 analysis, enabling a 10 s injection cycle time using an UV-ESI-QMS (Figure 7). The entire analysis of a
9 96-well microplate was performed in 17 min. In addition, this autosampler could be installed onto any
10 standard HPLC system¹³².
11
12
13

14
15 Analysis times lower than 2–5 min for relatively simple samples allow to process large sample pipelines
16 in a fast and reliable way uninterrupted in 24/7 routine operations in drug research and development.
17 This makes UHPLC-MS very attractive for combinatorial synthesis monitoring or drug metabolism and
18 pharmacokinetics studies (DMPK). When dealing with such short analysis times, the gradient delay
19 volume (the sum of all volume contributions from the point of gradient formation to the column head)
20 of a UHPLC system becomes critical for the overall sample throughput. A small gradient delay volume
21 is advantageous in terms of analysis time, since it will ensure the changing eluent composition reaches
22 the head of the column in a timely way. The gradient delay volume is composed of the mixer volume,
23 the sample loop, other fluidic parts of the autosampler and all connection tubing. Although fast LC
24 separations < 2 min can be achieved, it is important to keep in mind that the total cycling time is usually
25 2-3 times longer than the separation time due to the column equilibration, potential wash needle cycle,
26 and the time needed for preparing the sample injection¹³³. Chouchman and coworkers used a 5.0 mm
27 core-shell column for the ultra-rapid LC-MS/MS analysis of clozapine and norclozapine in human
28 plasma in gradient mode¹³⁴. The short total analysis time of 36 s made this approach extremely well-
29 suited for therapeutic drug monitoring, where the rapid availability of results allowed for fast dose
30 adjustments. The combination of an ultra-short column containing core-shell particles with a high flow
31 rate (2 mL/min) allowed a very short reconditioning time (16.4 s). Target compounds were detected
32 on a triple quadrupole MS in MRM with a dwell time of 3 ms per transition, which allowed acquiring
33 an average of 15 data points per chromatographic peak. In comparison with flow-injection analysis,
34 the analysis time was only slightly increased, while matrix effects were decreased due to the
35 chromatographic separation. Hettiarachchi and coworkers described the isolation of small molecule
36 and biomolecule crude mixtures at the microgram-scale (100–2500 g) in 1 min using an UHPLC-PDA-
37 ESI(+)-QMS set-up equipped with small-particle (1.8–3.5 μm), 50 \times 4.6 mm analytical C18 columns and
38 optimized flow rates (0.75–1.5 mL/min) with pressures averaging 10,000 psi¹³⁵. Recently, Xiang and
39 coworkers used a 2.7 cm (effective length), narrow open tubular (NOT) coated C18 column for an ultra-
40 fast gradient LC separation of 6 amino acids in less than 700 ms at a pressure of 20 MPa using a
41 fluorescence detector. According to the authors of that work, ultrafast NOT-LC will play an important
42 role in high-speed and high-throughput pharmaceutical analyses, once NOT-LC will be coupled with
43 MS (currently in development)¹³⁶.
44
45
46
47
48
49
50
51
52

53 3.3. Analysis and identification of impurities and degradation products

54
55 Impurities in pharmaceutical products are components that are responsible for changes in quality with
56 respect to safety and efficacy. Sources of impurities include starting materials, reagents, catalysts,
57 intermediates, solvents and degradation products formed during storage of the drug. Impurities are
58 classified into categories depending on their origin, composition and biological safety¹³⁷. Potential
59 genotoxic impurities (PGIs) and genotoxic impurities (GIs) or mutagenic impurities (MIs) include
60

1
2
3 compounds that result from chemical synthesis or degradation, and are DNA reactive and can hence
4 cause DNA damage and mutations. In the process of their identification and control, impurities are first
5 classified according to their mutagenic and carcinogenic potential¹³⁸. LC-MS is considered a mainstay
6 tool for their structural characterization. Critical practical aspects for the characterization of impurities
7 and degradation products by LC-MS were reported in a review by Narayanam et al. in 2014¹³⁹. Dousa
8 et al. reported the HILIC-ESI(+)-QMS determination of GIs of 2-chloro-N-(2-chloroethyl)-ethanamine
9 in the vortioxetine (drug used to treat major depressive disorder) manufacturing process. GIs were
10 quantified using the SIM acquisition mode at the 75 ppm level with respect to vortioxetine and the
11 method was developed and validated according to the requirements of regulatory agencies¹⁴⁰. Shelke
12 and coworkers recently reviewed the trends in analytical methods used for degradant, foreign matter,
13 genotoxic impurity and impurity profiling studies during the years 2013–2017¹⁴¹. Recently, Guo and
14 coworkers studied the degradation behavior of sutezolid (oxazolidinone anti-TB compound used for
15 the treatment of *M. Tuberculosis*) under different conditions, identifying 4 impurities by LC-ESI(+)-
16 QTOF-MS/MS. For the structure determination of the impurities, NMR analyses were also performed
17 to support LC-MS identification¹⁴². Guvvala et al. used a similar analytical setup (LC-ESI-QTOF-MS and
18 NMR) to determine six degradation products of cangrelor (antiplatelet parenteral drug) after it was
19 subjected to acid, base and peroxide stress conditions¹⁴³.

3.4. Analysis of chiral impurities

20
21
22 Chiral impurities are organic impurities present in drug substances, with a similar structure, but a
23 different spatial orientation around a chiral carbon atom in the molecule. Since many drugs are chiral,
24 increasing efforts are made by pharmaceutical companies to develop improved and well-controlled
25 enantioselective manufacturing processes. Drug substances with optical isomers typically have chiral
26 impurities. These impurities can have a different therapeutic and pharmacological profile compared to
27 the drug substance and can be toxic in some cases (e.g., the *S*-isomer of thalidomide is a teratogenic
28 impurity which causes birth defects¹⁴⁴). Therefore, these impurities should be controlled. Until the last
29 decade, chiral separations were typically performed with 5 or 3 μm fully porous particle (FPP) packed
30 columns and the times to separate enantiomeric mixtures easily exceeded 30 min, since the analytical
31 throughput of chiral LC-MS is primarily dependent on the efficiency of chiral columns¹⁴⁵. Since the
32 introduction of short columns, packed with very efficient chiral stationary phases (CSPs), such as sub-
33 2 μm FPPs and sub-3 μm SPPs, operated at high flow rates, the separation of racemates can nowadays
34 be done in very short times (often less than 1 s) in normal-, reversed-phase and HILIC conditions¹⁴⁶.
35 Chiral LC coupled with tandem MS combines the advantages of the highly selective separation capacity
36 of chiral LC and the superior sensitivity and specificity of MS detection. In this respect, ammonium
37 acetate and ammonium formate are increasingly used for the enantioseparation of basic drugs to
38 improve MS compatibility. Hellinghausen and coworkers used and compared four core-shell CSPs for
39 the enantiomeric LC-ESI(+)-QQQ-MS separation of 150 chiral amines with a variety in structural and
40 drug classes. The CSPs included macrocyclic glycopeptide-based CSPs (VancoShell and NicoShell),
41 cyclodextrin-based CSP (CDShell-RSP) and cyclofructan-based CSP (LarihShell-P). A resolution
42 between 1.5 and 2.5 was achieved for all 150 enantiomeric amines. Cyclofructan-based CSP performed
43 best for primary amines, while cyclodextrin- and glycopeptide-based CSPs separated a variety of
44 primary, secondary and tertiary amines. The glycopeptide-based CSP showed the best overall
45 performance, and provided the most complementary separation of the pharmaceuticals¹⁴⁷. An
46 efficient separation of miconazole enantiomers in RPLC mode was achieved on a polysaccharide-based
47 CSP using an ESI(+)-QQQ-MS in MRM mode¹⁴⁸. Hasan and coworkers developed three different LC-
48 ESI(+)-QQQ-MS assays for the quantitative chiral and achiral determination of ketamine (KET,
49 anesthetic drug) and its metabolites in human serum, urine and faeces. To separate the *S*- and *R*-
50 enantiomers of KET, n-KET and DHNK, a gradient was applied with a mobile phase containing
51
52
53
54
55
56
57
58
59
60

1
2
3 ammonium acetate and isopropanol on a protein-based CSP, while the enantioselective separation of
4 the HNK metabolites was done on an amylose-based CSP. An ESI-QQQ-MS was coupled to the LC
5 system for the detection¹⁴⁹. In another contribution, Guo and coworkers used a vancomycin-based
6 (macrocytic glycopeptide) 100 × 2.1 mm CSP core-shell 2.7 μm column, and compared its
7 performance with a 5 μm FFPs based analogue column. The core-shell column provided higher
8 efficiencies, a 2–5 times greater sensitivity and a shorter analysis time for a set of 22 basic
9 pharmaceutical drugs by using an ESI(+)-QQQ-MS detector¹⁵⁰. Todoroki et al developed a LC-ESI-QQQ-
10 MS/MS method to detect 11 chiral pharmaceuticals and their hepatic metabolites using a 3 μm, 150 ×
11 2.1 mm ovomucoid chiral column. All the pharmaceuticals examined were enantioseparated with a
12 resolution > 0.82¹⁵¹.
13

14 3.5. Pharmacokinetics/pharmacodynamics (PK/PD) studies

15 ADME-TOX (Absorption, Distribution, Metabolism, Excretion and Toxicity) studies are performed
16 during the discovery, lead optimization and preclinical development of new drug entities to provide
17 information to characterize these compounds based on their properties and predict their fate in the
18 human body after administration. Compounds with poor ADME properties are preferably removed as
19 early as possible in the discovery phase instead of during more costly drug development phases. The
20 overall process of finding the best candidate for clinical development is long and complicated, requiring
21 numerous studies and a constant redesigning of the chemical entities under development. The
22 strategy for drug discovery and development, including pharmacokinetics and toxicity studies, has
23 drastically changed in the last decade because of the improved understanding of the associated
24 molecular and cellular events, and the development of highly sensitive analytical instruments. LC-MS
25 based techniques are currently the most powerful and reliable analytical techniques in the field of
26 pharmacokinetics/pharmacodynamics (PK/PD) studies including therapeutic drug monitoring
27 (TDM)¹⁵².
28

29 In 2017, the tissue distribution and percutaneous absorption of indometacin (IND, non-steroidal
30 anti-inflammatory drug) patches were studied using commercial IND as a comparison. The
31 concentration of IND in skin, plasma, and muscle in mice was measured by UHPLC-ESI(+)-QQQ-MS in
32 MRM mode and the IND concentration in the dermis of rats was also monitored by microdialysis. It
33 was concluded that the examination of the tissue distribution and the application of a microdialysis
34 technique provided an effective means to evaluate indometacin pharmacokinetics¹⁵³. In the same
35 year, the pharmacokinetic profiles and tissue distribution characteristics of clevidipine
36 (antihypertensive drug) and its primary metabolite H152/81 were investigated by using a RPLC-ESI(+)-
37 QQQ-MS in MRM mode after intravenous administration to rats. The experimental data showed that
38 clevidipine was quickly eliminated from blood with a half-life of about 4.3 min and rapidly distributed
39 in all the investigated tissues after administration. The highest concentration of clevidipine was found
40 in the heart whereas the lowest concentration was detected in the liver. In addition, clevidipine was
41 almost undetectable in most tissues except for heart and brain at 90 min post-dosing, suggesting that
42 there was no apparent long-term accumulation in rat tissues. H152/81 was found at significant
43 concentration levels in all tissues at each time point¹⁵⁴. In 2018, Kucwaj-Brysz and coworkers, studied
44 the effect of the introduction/deletion and the mutual orientation of aromatic rings in animal models
45 in their search for selective and active serotonin 5-HT₇R antagonists among 3,5-disubstituted
46 arylpiperazine-imidazolidine-2,4-diones. To support the structure of synthesized drugs, NMR and LC-
47 ESI-QQQ were employed and *in-vitro* ADME-TOX studies were performed, reporting the low
48 cytotoxicity of the synthesized compounds¹⁵⁵. Recently, Tanner et al. studied drug-like properties
49 (microsomal/plasma protein binding, *in vitro* microsomal stability, lipophilicity, kinetic solubility and
50 passive permeability) and *in vivo* PK parameters of three decoquinone derivatives (potentially anti-TB
51
52
53
54
55
56
57
58
59
60

1
2
3 drugs) after oral and intravenous administration to male C57BL/6 mice using a RPLC-ESI-QIT-MS Article Online
4 system. The authors claimed that, although all three compounds (RMB₀₄₁, RMB₀₄₃, and RMB₀₇₃) had DOI: 10.1039/C9AN02145K
5 similar *in vitro* ADME properties, RMB₀₄₁ was the preferred compound to be taken forward in further
6 studies due to its longer *in vivo* half-life and higher bioavailability¹⁵⁶.
7
8
9

10 4. Conclusions

11
12 An overview of the main critical aspects and future trends in LC-MS based techniques in the
13 pharmaceutical field for the analysis of small pharmaceutical molecules is reported. In the last decade,
14 LC-MS based techniques have shown great potential for the analysis of pharmaceuticals, and have
15 played an important role in the study of drug metabolism, the discovery of new drug candidates and
16 the identification and characterization of degradation products and impurities in drug products. Recent
17 innovations in LC instruments, chromatographic modes and stationary phases have turned LC into the
18 golden standard for analytical strategies in the pharmaceutical field. In particular, the development of
19 miniaturized LC systems, such as microfluidic chip-based and more reliable nano-LC systems are
20 attracting attention and can potentially become more important in the future in pharmaceutical
21 analysis. Moreover, due to the commercialization of easy-to-operate and cheaper LRMS (in particular
22 quadrupole MS), and the easier accessibility of more performant MS technologies such as HRMS
23 instruments, MS will most likely expand even more as a preferred detection method for
24 pharmaceutical applications. Even if quadrupole MS technology is still predominant in pharmaceutical
25 analysis, HRMS is becoming not only feasible but also necessary for a confident determination in the
26 pharmaceutical field.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

5. References

View Article Online
DOI: 10.1039/C9AN02145K

- (1) Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L. Principles of Early Drug. *Br. J. Pharmacol.* **2011**, *162*, 1239–1249. <https://doi.org/10.1111/j.1476-5381.2010.01127.x>.
- (2) Bonfilio, R.; Gabriel, R. Recent Applications of Analytical Techniques for Quantitative Pharmaceutical Analysis : A Review Pharmaceutical Analysis. **2010**, *7* (4), 316–338.
- (3) Siddiqui, M. R.; AlOthman, Z. A.; Rahman, N. Analytical Techniques in Pharmaceutical Analysis: A Review. *Arabian Journal of Chemistry*. Elsevier B.V. February 2017, pp S1409–S1421. <https://doi.org/10.1016/j.arabjc.2013.04.016>.
- (4) Ermer, J.; Vogel, M. Applications of Hyphenated LC-MS Techniques in Pharmaceutical Analysis. *Biomedical Chromatography*. 2000, pp 373–383. [https://doi.org/10.1002/1099-0801\(200010\)14:6<373::AID-BMC29>3.0.CO;2-S](https://doi.org/10.1002/1099-0801(200010)14:6<373::AID-BMC29>3.0.CO;2-S).
- (5) Gadepalli, S. G.; Deme, P.; Kuncha, M.; Sistla, R. Simultaneous Determination of Amlodipine, Valsartan and Hydrochlorothiazide by LC-ESI-MS/MS and Its Application to Pharmacokinetics in Rats. *J. Pharm. Anal.* **2014**, *4* (6), 399–406. <https://doi.org/10.1016/j.jpba.2013.12.003>.
- (6) Kostić, N.; Dotsikas, Y.; Jović, N.; Stevanović, G.; Malenović, A.; Medenica, M. Quantitation of Pregabalin in Dried Blood Spots and Dried Plasma Spots by Validated LC-MS/MS Methods. *J. Pharm. Biomed. Anal.* **2015**, *109*, 79–84. <https://doi.org/10.1016/j.jpba.2015.02.023>.
- (7) De Meulder, M.; Waldron, M. P.; Li, L.; Peay, M. G.; Tingler, M. J.; Hidy, B. J.; Verhaeghe, T.; Jenkins, R. G. Development and Validation of HILIC-ESI/MS/MS Methods for Simultaneous Quantitation of Several Antipsychotics in Human Plasma and Blood. *Bioanalysis* **2016**, *8* (8), 765–794. <https://doi.org/10.4155/bio.16.27>.
- (8) Loos, G.; Van Schepdael, A.; Cabooter, D. Quantitative Mass Spectrometry Methods for Pharmaceutical Analysis. *Philos. Trans. R. Soc. A Math. Phys. Eng. Sci.* **2016**, *374* (2079). <https://doi.org/10.1098/rsta.2015.0366>.
- (9) Rao, C. H. B. LC/MS : AN ESSENTIAL TOOL IN DRUG DEVELOPMENT. *Int. J. Adv. Pharm. Anal.* **2011**, *1* (2), 24–37. <https://doi.org/10.7439/ijapa.v1i2.10>.
- (10) Ortega, S.; Santos Neto, A. dos; Lancas, F. M. Development and Optimization of a Fast Method for Determination of Statins in Human Plasma Using Microextraction by Packed Sorbent (MEPS) Followed by Ultra High-Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC-MS/MS). *Anal. Methods* **2017**, *9*, 3039–3048. <https://doi.org/10.1039/C7AY00185A>.
- (11) Farhan, N.; Fitzpatrick, S.; Shim, Y. M.; Paige, M.; Chow, D. S. Ultrapressure Liquid Chromatography – Tandem Mass Spectrometry Assay Using Atmospheric Pressure Photoionization (UPLC-APPI-MS / MS) for Quantification of 4-Methoxydiphenylmethane in Pharmacokinetic Evaluation. *J. Pharm. Biomed. Anal.* **2016**, *128*, 46–52. <https://doi.org/10.1016/j.jpba.2016.05.014>.
- (12) Zheng, L.; Zheng, F. Development and Validation of an LC-APCI-MS/MS Method for the Determination of Phenethyl Isothiocyanate in Human Plasma. *Biomed. Chromatogr.* **2015**, *29* (4), 619–625. <https://doi.org/10.1002/bmc.3323>.
- (13) Kim, D.; Park, J. B.; Choi, W. K.; Lee, S. J.; Lim, I.; Bae, S. K. Simultaneous Determination of B-Sitosterol, Campesterol, and Stigmasterol in Rat Plasma by Using LC-APCI-MS/MS: Application in a Pharmacokinetic Study of a Titrated Extract of the Unsaponifiable Fraction of Zea Mays L. *J. Sep. Sci.* **2016**, *39* (21), 4060–4070. <https://doi.org/10.1002/jssc.201600589>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (14) A., V. B. R.; Yusop, Z.; Jaafar, J.; Aris, A. B.; Majid, Z. A.; Umar, K.; Talib, J. Development and Validation of a Selective, Sensitive and Stability Indicating UPLC-MS/MS Method for Rapid, Simultaneous Determination of Six Process Related Impurities in Darunavir Drug Substance. *J. Pharm. Biomed. Anal.* **2016**, *128*, 141–148. <https://doi.org/10.1016/j.jpba.2016.05.026>. New Article Online
DOI: 10.1039/C9AN02145K
- (15) Beccaria, M.; Inferrera, V.; Rigano, F.; Gorynski, K.; Purcaro, G.; Pawliszyn, J.; Dugo, P.; Mondello, L. Highly Informative Multiclass Profiling of Lipids by Ultra-High Performance Liquid Chromatography – Low Resolution (Quadrupole) Mass Spectrometry by Using Electrospray Ionization and Atmospheric Pressure Chemical Ionization Interfaces. *J. Chromatogr. A* **2017**. <https://doi.org/10.1016/j.chroma.2017.06.017>.
- (16) Yamada, M.; Kita, Y.; Kohira, T.; Yoshida, K. A Comprehensive Quantification Method for Eicosanoids and Related Compounds by Using Liquid Chromatography / Mass Spectrometry with High Speed Continuous Ionization Polarity Switching. *J. Chromatogr. B* **2015**, *995–996*, 74–84. <https://doi.org/10.1016/j.jchromb.2015.05.015>.
- (17) Galaon, T.; Vacaresteanu, C.; Anghel, D. F.; David, V. Simultaneous ESI-APCI(+) Ionization and Fragmentation Pathways for Nine Benzodiazepines and Zolpidem Using Single Quadrupole LC-MS. *Drug Test. Anal.* **2014**, *6* (5), 439–450. <https://doi.org/10.1002/dta.1526>.
- (18) Josephs, R. D.; Daireaux, A.; Choteau, T.; Westwood, S.; Wielgosz, R. I. Normal Phase-Liquid Chromatography-Tandem Mass Spectrometry with Atmospheric Pressure Photoionization for the Purity Assessment of 17 β -Estradiol. *Anal. Bioanal. Chem.* **2015**, *407* (11), 3147–3157. <https://doi.org/10.1007/s00216-014-8189-6>.
- (19) McCulloch, R. D.; Robb, D.; Blades, M. Development of a Next-Generation Field-Free Atmospheric Pressure Photoionization Source for Liquid Chromatography/Mass Spectrometry. *Rapid Commun. Mass Spectrom.* **2016**, *30* (2), 333–339. <https://doi.org/10.1002/rcm.7444>.
- (20) Mcculloch, R. D.; Robb, D. B. Field-Free Atmospheric Pressure Photoionization – Liquid Chromatography – Mass Spectrometry for the Analysis of Steroids within Complex Biological Matrices. **2017**. <https://doi.org/10.1021/acs.analchem.7b00157>.
- (21) Lubin, A.; Bajic, S.; Cabooter, D.; Augustijns, P.; Cuyckens, F. Atmospheric Pressure Ionization Using a High Voltage Target Compared to Electrospray Ionization. *J. Am. Soc. Mass Spectrom.* **2016**. <https://doi.org/10.1007/s13361-016-1537-3>.
- (22) Lubin, A.; Vries, R. De; Cabooter, D.; Augustijns, P.; Cuyckens, F. Journal of Pharmaceutical and Biomedical Analysis An Atmospheric Pressure Ionization Source Using a High Voltage Target Compared to Electrospray Ionization for the LC / MS Analysis of Pharmaceutical Compounds. *J. Pharm. Biomed. Anal.* **2017**, *142*, 225–231. <https://doi.org/10.1016/j.jpba.2017.05.003>.
- (23) Lubin, A.; Geerinckx, S.; Bajic, S.; Cabooter, D.; Augustijns, P.; Cuyckens, F.; Vreeken, R. J. Enhanced Performance for the Analysis of Prostaglandins and Thromboxanes by Liquid Chromatography-Tandem Mass Spectrometry Using a New Atmospheric Pressure Ionization Source. *J. Chromatogr. A* **2016**, *1440*, 260–265. <https://doi.org/10.1016/j.chroma.2016.02.055>.
- (24) Ciclet, O.; Barron, D.; Bajic, S.; Veuthey, J.; Guillaume, D.; Perrenoud, A. G. Natural Compounds Analysis Using Liquid and Supercritical Fluid Chromatography Hyphenated to Mass Spectrometry: Evaluation of a New Design of Atmospheric Pressure Ionization Source. *J. Chromatogr. B* **2018**, *1083* (March), 1–11. <https://doi.org/10.1016/j.jchromb.2018.02.037>.
- (25) Fenner, M. A.; Chakrabarty, S.; Wang, B.; Pagnotti, V. S.; Hoang, K.; Trimpin, S.; Mcewen, C. N. An LC/MS Method Providing Improved Sensitivity: Electrospray Ionization Inlet. **2017**. <https://doi.org/10.1021/acs.analchem.6b05172>.

- 1
2
3 (26) Khatal, L.; Gaur, A.; Naphade, A.; Kandikere, V. Impact of APCI Ionization Source in Liquid Chromatography Tandem Mass Spectrometry Based Tissue Distribution Studies. *2016*, No. April, 1676–1685. <https://doi.org/10.1002/bmc.3740>. View Article Online
DOI: 10.1039/C9AN02145K
- 4
5
6
7 (27) Trufelli, H.; Palma, P.; Famiglini, G.; Cappiello, A. An Overview of Matrix Effects in Liquid Chromatography-Mass Spectrometry. *Mass Spectrom. Rev.* **2011**, *30*, 491–509. <https://doi.org/10.1002/mas>.
- 8
9
10
11 (28) Magrini, L.; Famiglini, G.; Palma, P.; Termopoli, V.; Cappiello, A. Boosting the Detection Potential of Liquid Chromatography-Electron Ionization Mass Spectrometry Using a Ceramic Coated Ion Source. *J. Am. Soc. Mass Spectrom.* **2016**, *27* (1), 153–160. <https://doi.org/10.1007/s13361-015-1257-0>.
- 12
13
14 (29) Famiglini, G.; Termopoli, V.; Palma, P.; Cappiello, A. Liquid Chromatography-Electron Ionization Tandem Mass Spectrometry with the Direct-El Interface in the Fast Determination of Diazepam and Flunitrazepam in Alcoholic Beverages. *Electrophoresis* **2016**, *37* (7–8), 1048–1054. <https://doi.org/10.1002/elps.201500517>.
- 15
16
17 (30) Termopoli, V.; Famiglini, G.; Palma, P.; Piergiovanni, M.; Cappiello, A. Atmospheric Pressure Vaporization Mechanism for Coupling a Liquid Phase with Electron Ionization Mass Spectrometry. *Anal. Chem.* **2017**, *89* (3), 2049–2056. <https://doi.org/10.1021/acs.analchem.6b04646>.
- 18
19
20 (31) Termopoli, V.; Famiglini, G.; Palma, P.; Piergiovanni, M.; Rocio-bautista, P.; Francesca, M.; Cappiello, A.; Saeed, M.; Perry, S. Evaluation of a Liquid Electron Ionization Liquid Chromatography – Mass Spectrometry Interface. *J. Chromatogr. A* **2019**, *1591*, 120–130. <https://doi.org/10.1016/j.chroma.2019.01.034>.
- 21
22
23 (32) Beccaria, M.; Franchina, F. A.; Nasir, M.; Mellors, T.; Hill, J. E.; Purcaro, G. Investigation of Mycobacteria Fatty Acid Profile Using Different Ionization Energies in GC – MS. *Anal. Bioanal. Chem.* **2018**, *410*, 7987–7996.
- 24
25
26 (33) Seemann, B.; Alon, T.; Tsizin, S.; Fialkov, A. B.; Amirav, A. Electron Ionization LC-MS with Supersonic Molecular Beams - The New Concept, Benefits and Applications. *J. Mass Spectrom.* **2015**, *50* (11), 1252–1263. <https://doi.org/10.1002/jms.3695>.
- 27
28
29 (34) Rigano, F.; Tranchida, P. Q.; Dugo, P.; Mondello, L. High-Performance Liquid Chromatography Combined with Electron Ionization Mass Spectrometry: A Review. *Trends Anal. Chem.* **2019**, *118*, 112–122. <https://doi.org/10.1016/j.trac.2019.05.032>.
- 30
31
32 (35) Lin, L.; Lin, H.; Zhang, M.; Dong, X.; Yin, X.; Qu, C.; Ni, J. Types, Principle, and Characteristics of Tandem High-Resolution Mass Spectrometry and Its Applications. *RSC Adv.* **2015**, *5* (130), 107623–107636. <https://doi.org/10.1039/C5RA22856E>.
- 33
34
35 (36) Olsen, J. V.; de Godoy, L. M. F.; Li, G.; Macek, B.; Mortensen, P.; Pesch, R.; Makarov, A.; Lange, O.; Horning, S.; Mann, M. Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-Trap. *Mol. Cell. Proteomics* **2005**, *4* (12), 2010–2021. <https://doi.org/10.1074/mcp.T500030-MCP200>.
- 36
37
38 (37) Holčapek, M.; Jirásko, R.; Lísa, M. Recent Developments in Liquid Chromatography-Mass Spectrometry and Related Techniques. *J. Chromatogr. A* **2012**, *1259*, 3–15. <https://doi.org/10.1016/j.chroma.2012.08.072>.
- 39
40
41 (38) Bu, X.; Regalado, E. L.; Hamilton, S. E.; Welch, C. J. The Emergence of Low-Cost Compact Mass Spectrometry Detectors for Chromatographic Analysis. *TrAC - Trends Anal. Chem.* **2016**, *82*, 22–34. <https://doi.org/10.1016/j.trac.2016.04.025>.
- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (39) Snyder, D. T.; Pulliam, C. J.; Ouyang, Z.; Cooks, R. G. Miniature and Fieldable Mass Spectrometers: Recent Advances. *Anal. Chem.* **2016**, *88* (1), 2–29. View Article Online
DOI: 10.1039/C9AN02145K
<https://doi.org/10.1021/acs.analchem.5b03070>.
- (40) Bu, X.; Yang, J.; Gong, X.; Welch, C. J. Evaluation of a Compact Mass Spectrometer for Routine Support of Pharmaceutical Chemistry. *J. Pharm. Biomed. Anal.* **2014**, *94*, 139–144.
<https://doi.org/10.1016/j.jpba.2014.01.029>.
- (41) Gao, J.; Ceglia, S. S.; Jones, M. D.; Simeone, J.; Antwerp, J. Van; Zhang, L. K.; Ross, C. W.; Helmy, R. A Novel Compact Mass Detection Platform for the Open Access (OA) Environment in Drug Discovery and Early Development. *J. Pharm. Biomed. Anal.* **2016**, *122*, 1–8.
<https://doi.org/10.1016/j.jpba.2016.01.017>.
- (42) Kaufmann, A.; Butcher, P.; Maden, K.; Walker, S.; Widmer, M. Quantitative and Confirmative Performance of Liquid Chromatography Coupled to High - Resolution Mass Spectrometry Compared to Tandem Mass Spectrometry. *Rapid Commun. Mass Spectrom.* **2011**, *25*.
<https://doi.org/DOI: 10.1002/rcm.4952>.
- (43) Grund, B.; Marvin, L.; Rochat, B. Quantitative Performance of a Quadrupole-Orbitrap-MS in Targeted LC-MS Determinations of Small Molecules. *J. Pharm. Biomed. Anal.* **2016**, *124*, 48–56. <https://doi.org/10.1016/j.jpba.2016.02.025>.
- (44) Zhang, Y.; Zhang, R. Recent Advances in Analytical Methods for the Therapeutic Drug Monitoring of Immunosuppressive Drugs. **2017**, No. April, 81–94.
<https://doi.org/10.1002/dta.2290>.
- (45) Taylor, P. J.; Tai, C.; Franklin, M. E.; Pillans, P. I. The Current Role of Liquid Chromatography-Tandem Mass Spectrometry in Therapeutic Drug Monitoring of Immunosuppressant and Antiretroviral Drugs. *Clin. Biochem.* **2011**, *44* (1), 14–20.
<https://doi.org/10.1016/j.clinbiochem.2010.06.012>.
- (46) Gallien, S.; Bourmaud, A.; Yoon, S.; Domon, B. Technical Considerations for Large-Scale Parallel Reaction Monitoring Analysis. *J. Proteomics* **2013**, *100*, 147–159.
<https://doi.org/10.1016/j.jprot.2013.10.029>.
- (47) Mazzucchelli, S.; Ciuffreda, P.; Ravelli, A.; Ottria, R.; Corsi, F. LC – MS/MS Method Development for Quantification of Doxorubicin and Its Metabolite 13 - Hydroxy Doxorubicin in Mice Biological Matrices: Application to a Pharmaco - Delivery Study. **2017**, No. October 2016, 1–10. <https://doi.org/10.1002/bmc.3863>.
- (48) Murray, K. K.; Boyd, R. K.; Eberlin, M. N.; Langley, G. J.; Li, L.; Naito, Y. Definitions of Terms Relating to Mass Spectrometry (IUPAC Recommendations 2013)*. *Pure Appl. Chem.* **2013**, *85* (7), 1515–1609. <https://doi.org/10.1351/PAC-REC-06-04-06>.
- (49) Fabresse, N.; Larabi, I. A.; Stratton, T.; Mistrik, R.; Pfau, G.; Lorin de la Grandmaison, G.; Etting, I.; Delyle, S. G.; Alvarez, J. C. Development of a Sensitive Untargeted Liquid Chromatography – High Resolution Mass Spectrometry Screening Devoted to Hair Analysis through a Shared MS2 Spectra Database : A Step toward Early Detection of New Psychoactive Substances. *Drug Test. Anal.* **2019**, *11* (5), 697–708. <https://doi.org/10.1002/dta.2535>.
- (50) Noble, C.; Dalsgaard, P. W.; Johansen, S. S.; Linnet, K. Application of a Screening Method for Fentanyl and Its Analogues Using UHPLC - QTOF - MS with Data - Independent Acquisition (DIA) in MS E Mode and Retrospective Analysis of Authentic Forensic Blood Samples. *Drug Test. Anal.* **2018**, *10* (August 2017), 651–662. <https://doi.org/10.1002/dta.2263>.
- (51) Arnhard, K.; Gottschall, A.; Pitterl, F.; Oberacher, H. Applying ‘ Sequential Windowed

Acquisition of All Theoretical Fragment Ion Mass Spectra ' (SWATH) for Systematic Toxicological Analysis with Liquid Chromatography-High-Resolution Tandem Mass Spectrometry. *Anal. Bioanal. Chem. Bioanal Chem* **2015**, *407*, 405–414. <https://doi.org/10.1007/s00216-014-8262-1>. View Article Online
DOI: 10.1039/C9AN02145K

- (52) Hu, A.; Noble, W. S.; Wolf-yadlin, A. Technical Advances in Proteomics : New Developments in Data-Independent Acquisition. *F1000Research* **2016**, *5*, 1–12.
- (53) Rochat, B. From Targeted Quantification to Untargeted Metabolomics: Why LC-High-Resolution-MS Will Become a Key Instrument in Clinical Labs. *TrAC - Trends Anal. Chem.* **2016**, *84*, 151–164. <https://doi.org/10.1016/j.trac.2016.02.009>.
- (54) Rochat, B. Proposed Confidence Scale and ID Score Using High Resolution MS Data. *J. Am. Soc. Mass Spectrom.* **2017**, 709–723. <https://doi.org/10.1007/s13361-016-1556-0>.
- (55) Kaufmann, A.; Butcher, P.; Maden, K.; Walker, S.; Widmer, M. Comprehensive Comparison of Liquid Chromatography Selectivity as Provided by Two Types of Liquid Chromatography Detectors (High Resolution Mass Spectrometry and Tandem Mass Spectrometry): “ Where Is the Crossover Point ?” *Anal. Chim. Acta* **2010**, *673* (1), 60–72. <https://doi.org/10.1016/j.aca.2010.05.020>.
- (56) Dahmane, E.; Boccard, J.; Csajka, C.; Rudaz, S.; Décosterd, L.; Genin, E.; Duret, B.; Bromirski, M.; Zaman, K.; Testa, B.; et al. Quantitative Monitoring of Tamoxifen in Human Plasma Extended to 40 Metabolites Using Liquid-Chromatography High-Resolution Mass Spectrometry: New Investigation Capabilities for Clinical Pharmacology. *Anal. Bioanal. Chem.* **2014**, *406* (11), 2627–2640. <https://doi.org/10.1007/s00216-014-7682-2>.
- (57) Rochat, B.; Peduzzi, D.; McMullen, J.; Favre, A.; Kottelat, E.; Favrat, B.; Tissot, J. D.; Angelillo-Scherrer, A.; Bromirski, M.; Waldvogel, S. Validation of Hepcidin Quantification in Plasma Using LC-HRMS and Discovery of a New Hepcidin Isoform. *Bioanalysis* **2013**, *5* (20), 2509–2520. <https://doi.org/10.4155/bio.13.225>.
- (58) Vereyken, L.; Dillen, L.; Vreeken, R. J.; Cuyckens, F. High-Resolution Mass Spectrometry Quantification: Impact of Differences in Data Processing of Centroid and Continuum Data. *J. Am. Soc. Mass Spectrom.* **2019**, *30*, 203–212. <https://doi.org/10.1007/s13361-018-2101-0>.
- (59) Dubbelman, A.; Cuyckens, F.; Dillen, L.; Gross, G.; Vreeken, R. J.; Hankemeier, T. Mass Spectrometric Recommendations for Quan / Qual Analysis Using Liquid-Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry. *Anal. Chim. Acta* **2018**, *1020*, 62–75. <https://doi.org/10.1016/j.aca.2018.02.055>.
- (60) Sturm, R. M.; Jones, B. R.; Mulvana, D. E. HRMS Using a Q-Exactive Series Mass Spectrometer for Regulated Quantitative Bioanalysis : How , When , and Why to Implement. *Bioanalysis* **2016**, *8*, 1709–1721.
- (61) Kind, T.; Fiehn, O. Metabolomic Database Annotations via Query of Elemental Compositions: Mass Accuracy Is Insufficient Even at Less than 1 Ppm. *BMC Bioinformatics* **2006**, *7*, 1–10. <https://doi.org/10.1186/1471-2105-7-234>.
- (62) Wang, J. W.; Chiang, M. H.; Lu, C. M.; Tsai, T. H. Determination the Active Compounds of Herbal Preparation by UHPLC-MS/MS and Its Application on the Preclinical Pharmacokinetics of Pure Ephedrine, Single Herbal Extract of Ephedra, and a Multiple Herbal Preparation in Rats. *J. Chromatogr. B* **2016**, *1026*, 152–161. <https://doi.org/10.1016/j.jchromb.2015.12.027>.
- (63) Hroch, M.; Mičuda, S.; Havelek, R.; Cermanová, J.; Cahlíková, L.; Hošťálková, A.; Hulcová, D.; Řezáčová, M. LC-MS/MS Method for the Determination of Haemanthamine in Rat Plasma, Bile

- and Urine and Its Application to a Pilot Pharmacokinetic Study. *Biomed. Chromatogr.* **2016**, *30* (7), 1083–1091. <https://doi.org/10.1002/bmc.3653>. Article Online
DOI: 10.1039/C9AN02145K
- (64) De Nicolò, A.; Avataneo, V.; Rabbia, F.; Sciandra, M.; Tosello, F.; Cusato, J.; Perlo, E.; Mulatero, P.; Veglio, F.; Di Perri, G.; et al. UHPLC–MS/MS Method with Sample Dilution to Test Therapeutic Adherence through Quantification of Ten Antihypertensive Drugs in Urine Samples. *J. Pharm. Biomed. Anal.* **2017**, *142*, 279–285. <https://doi.org/10.1016/j.jpba.2017.05.018>.
- (65) Fekete, S.; Sadat-noorbakhsh, V.; Schelling, C.; Molnár, I.; Guillarme, D.; Rudaz, S.; Veuthey, J. Implementation of a Generic Liquid Chromatographic Method Development Workflow : Application to the Analysis of Phytocannabinoids and Cannabis Sativa Extracts. *J. Pharm. Biomed. Anal.* **2018**, *155*, 116–124. <https://doi.org/10.1016/j.jpba.2018.03.059>.
- (66) Fekete, S.; Schappler, J.; Veuthey, J.-L.; Guillarme, D. Current and Future Trends in UHPLC. *Trends Anal. Chem.* **2014**, *63*, 2–13. <https://doi.org/10.1016/j.trac.2014.08.007>.
- (67) Gumustas, M.; Zalewski, P.; Ozkan, S. A.; Uslu, B. *The History of the Core – Shell Particles and Applications in Active Pharmaceutical Ingredients Via Liquid Chromatography*; Springer Berlin Heidelberg, 2019; Vol. 82. <https://doi.org/10.1007/s10337-018-3670-6>.
- (68) Cabooter, D.; Lestremau, F.; Lynen, F.; Sandra, P.; Desmet, G. Kinetic Plot Method as a Tool to Design Coupled Column Systems Producing 100,000 Theoretical Plates in the Shortest Possible Time. *J. Chromatogr. A* **2008**, *1212* (1–2), 23–34. <https://doi.org/10.1016/j.chroma.2008.09.106>.
- (69) Ricardo, V.; Junior, A.; Lanc, F. M.; Eugênia, M.; Queiroz, C. Evaluation of Superficially Porous and Fully Porous Columns for Analysis of Drugs in Plasma Samples by UHPLC – MS / MS. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2017**, *1048*, 1–9. <https://doi.org/10.1016/j.jchromb.2017.02.002>.
- (70) Virgiliou, C.; Sampsonidis, I.; Gika, H. G.; Raikos, N.; Theodoridis, G. A. Development and Validation of a HILIC-MS/MS Multitargeted Method for Metabolomics Applications. *Electrophoresis* **2015**, *36* (18), 2215–2225. <https://doi.org/10.1002/elps.201500208>.
- (71) King, A. M.; Mullin, L. G.; Wilson, I. D.; Coen, M.; Rainville, P. D.; Plumb, R. S.; Gethings, L. A.; Maker, G.; Trengove, R. Development of a Rapid Profiling Method for the Analysis of Polar Analytes in Urine Using HILIC–MS and Ion Mobility Enabled HILIC–MS. *Metabolomics* **2019**, *15* (2), 1–11. <https://doi.org/10.1007/s11306-019-1474-9>.
- (72) Buckenmaier, S.; Miller, C. A.; van de Goor, T.; Dittmann, M. M. Instrument Contributions to Resolution and Sensitivity in Ultra High Performance Liquid Chromatography Using Small Bore Columns: Comparison of Diode Array and Triple Quadrupole Mass Spectrometry Detection. *J. Chromatogr. A* **2015**, *1377*, 64–74. <https://doi.org/10.1016/j.chroma.2014.11.086>.
- (73) Desmet, G.; Broeckhoven, K. Extra-Column Band Broadening Effects in Contemporary Liquid Chromatography: Causes and Solutions. *TrAC - Trends Anal. Chem.* **2019**, *119*, 115619. <https://doi.org/10.1016/j.trac.2019.115619>.
- (74) Spaggiari, D.; Fekete, S.; Eugster, P. J.; Veuthey, J. L.; Geiser, L.; Rudaz, S.; Guillarme, D. Contribution of Various Types of Liquid Chromatography-Mass Spectrometry Instruments to Band Broadening in Fast Analysis. *J. Chromatogr. A* **2013**, *1310*, 45–55. <https://doi.org/10.1016/j.chroma.2013.08.001>.
- (75) Rodriguez-Aller, M.; Gurny, R.; Veuthey, J.-L.; Guillarme, D. Coupling Ultra High-Pressure Liquid Chromatography with Mass Spectrometry: Constraints and Possible Applications. *J.*

- Chromatogr. A* **2013**, *1292*, 2–18. <https://doi.org/10.1016/j.chroma.2012.09.061>. View Article Online
DOI: 10.1039/C9AN02145K
- (76) Schreiber, L.; Hutta, M. Fast Ultra-high-performance Liquid Chromatography with Diode Array and Mass Spectrometry Method for Determination of Tadalafil Drug Substance and Its Impurities. *Biomed. Chromatogr.* **2017**, No. May, 1–8. <https://doi.org/10.1002/bmc.4020>.
- (77) Wang, Z.; Sun, W.; Lin, Z.; Sun, R.; Huang, C.; Ye, W.; Dong, Y.; Zhang, X.; Chen, R. Analysis A UHPLC-MS/MS Method Coupled with Liquid-Liquid Extraction for the Quantitation of Phenacetin, Omeprazole, Metoprolol, Midazolam and Their Metabolites in Rat Plasma and Its Application to the Study of Four CYP450 Activities. *J. Pharm. Biomed. Anal.* **2019**, *163*, 204–210. <https://doi.org/10.1016/j.jpba.2018.10.012>.
- (78) Rakuša, C. T.; Rožkar, R.; Klan, A.; Andrejč, I.; Lušin, T. T.; Faganeli, N.; Grabnar, I.; Mrhar, A.; Kristl, A.; Trontelj, J. Fast and Simple LC-MS/MS Method for Rifampicin Quantification in Human Plasma. *Int. J. Anal. Chem.* **2019**, *2019*.
- (79) Miyadera, Y.; Naito, T.; Yamada, T.; Kawakami, J. Simple LC-MS/MS Methods Using Core – Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. *Ther. Drug Monit.* **2018**, *40* (5), 589–595.
- (80) Loos, G.; Shoykhet, K.; Dittmann, M.; Cabooter, D. Restriction Capillaries as an Innovative Mixing Unit for Intermediate Mobile Phase Exchange in Multidimensional Analysis. *J. Chromatogr. A* **2017**, *1497*. <https://doi.org/10.1016/j.chroma.2017.03.036>.
- (81) Cabooter, D.; Choikhet, K.; Lestremau, F.; Dittmann, M.; Desmet, G. Towards a Generic Variable Column Length Method Development Strategy for Samples with a Large Variety in Polarity. *J. Chromatogr. A* **2014**, *1372*. <https://doi.org/10.1016/j.chroma.2014.11.006>.
- (82) Petersson, P.; Haselmann, K.; Buckenmaier, S. Multiple Heart-Cutting Two Dimensional Liquid Chromatography Mass Spectrometry: Towards Real Time Determination of Related Impurities of Bio-Pharmaceuticals in Salt Based Separation Methods. *J. Chromatogr. A* **2016**, *1468*, 95–101. <https://doi.org/10.1016/j.chroma.2016.09.023>.
- (83) Wang, C.; Chen, S.; Brailsford, J. A.; Yamniuk, A. P.; Tymiak, A. A.; Zhang, Y. Characterization and Quantification of Histidine Degradation in Therapeutic Protein Formulations by Size Exclusion-Hydrophilic Interaction Two Dimensional-Liquid Chromatography with Stable-Isotope Labeling Mass Spectrometry. *J. Chromatogr. A* **2015**, *1426*, 133–139. <https://doi.org/10.1016/j.chroma.2015.11.065>.
- (84) Stoll, D. R. Recent Advances in 2D-LC for Bioanalysis. *Bioanalysis* **2015**, *7* (24), 3125–3142. <https://doi.org/10.4155/bio.15.223>.
- (85) Dai, L.; Yeh, G. K.; Ran, Y.; Yehl, P.; Zhang, K. Compatibility Study of a Parenteral Microdose Polyethylene Glycol Formulation in Medical Devices and Identification of Degradation Impurity by 2D-LC/MS. *J. Pharm. Biomed. Anal.* **2017**, *137*, 182–188. <https://doi.org/10.1016/j.jpba.2017.01.036>.
- (86) Battisti, U. M.; Citti, C.; Larini, M.; Ciccarella, G.; Stasiak, N.; Troisi, L.; Braghiroli, D.; Parenti, C.; Zoli, M.; Cannazza, G. “Heart-Cut” Bidimensional Achiral-Chiral Liquid Chromatography Applied to the Evaluation of Stereoselective Metabolism, in Vivo Biological Activity and Brain Response to Chiral Drug Candidates Targeting the Central Nervous System. *J. Chromatogr. A* **2016**, *1443*, 152–161. <https://doi.org/10.1016/j.chroma.2016.03.027>.
- (87) Wang, H.; Xu, T.; Yuan, J. The Use of Online Heart-Cutting High-Performance Liquid Chromatography Coupled with Linear Ion Trap Mass Spectrometry in the Identification of Impurities in Vidarabine Monophosphate. *J. Sep. Sci.* **2017**, *40* (8), 1674–1685.

<https://doi.org/10.1002/jssc.201601320>.

View Article Online
DOI: 10.1039/C9AN02145K

- (88) Wang, H.; Xie, S. Identification of Impurities in 5-Aminolevulinic Acid by Two-Dimensional Column-Switching Liquid Chromatography Coupled with Linear Ion Trap Mass Spectrometry. *Chromatographia* **2016**, *79* (21–22), 1469–1478. <https://doi.org/10.1007/s10337-016-3165-2>.
- (89) Wang, J.; Xu, Y.; Wen, C.; Wang, Z. Application of a Trap-Free Two-Dimensional Liquid Chromatography Combined with Ion Trap/Time-of-Flight Mass Spectrometry for Separation and Characterization of Impurities and Isomers in Cefpiramide. *Anal. Chim. Acta* **2017**, 1–13. <https://doi.org/10.1002/rcm.7934>.
- (90) Wang, J.; Liu, G.; Xu, Y.; Zhu, B.; Wang, Z. Separation and Characterization of New Components and Impurities in Leucomycin by Multiple Heart - Cutting Two - Dimensional Liquid Chromatography Combined with Ion Trap / Time - of - Flight Mass Spectrometry. *Chromatographia* **2019**, 1333–1344. <https://doi.org/10.1007/s10337-019-03754-5>.
- (91) de Vries, R.; Vereyken, L.; François, I.; Dillen, L.; Vreeken, R. J.; Cuyckens, F. High Sensitivity and Selectivity in Quantitative Analysis of Drugs in Biological Samples Using 4-Column Multidimensional Micro-UHPLC-MS Enabling Enhanced Sample Loading Capacity. *Anal. Chim. Acta* **2017**, *989*, 104–111. <https://doi.org/10.1016/j.aca.2017.07.067>.
- (92) Yu, H.; Choi, M.; Byoungduck, J. J.; Park, B.; Seo, H. Y.; Jeong, C.-H.; Bae, J.; Lee, S. Development of a Column-Switching LC-MS/MS Method of Tramadol and Its Metabolites in Hair and Application to a Pharmacogenetic Study. *Arch. Pharm. Res.* **2018**, *41* (5), 554–563. <https://doi.org/10.1007/s12272-018-1013-7>.
- (93) Pirok, B. W. K.; Gargano, A.; Schoenmakers, P. J. Optimizing Separations in Online Comprehensive Two-Dimensional Liquid Chromatography. *J. Sep. Sci.* **2018**, *41* (68–98). <https://doi.org/10.1002/jssc.201700863>.
- (94) Sandra, K.; Sandra, P. The Opportunities of 2D-LC in the Analysis of Monoclonal Antibodies. *Bioanalysis* **2015**, *7* (22), 2843–2847. <https://doi.org/10.4155/bio.15.210>.
- (95) Willmann, L.; Erbes, T.; Krieger, S.; Trafkowski, J.; Rodamer, M.; Kammerer, B. Metabolome Analysis via Comprehensive Two-Dimensional Liquid Chromatography: Identification of Modified Nucleosides from RNA Metabolism. *Anal. Bioanal. Chem.* **2015**, *407* (13), 3555–3566. <https://doi.org/10.1007/s00216-015-8516-6>.
- (96) Vonk, R. J.; Gargano, A. F. G.; Davydova, E.; Dekker, H. L.; Eeltink, S.; de Koning, L. J.; Schoenmakers, P. J. Comprehensive Two-Dimensional Liquid Chromatography with Stationary-Phase-Assisted Modulation Coupled to High-Resolution Mass Spectrometry Applied to Proteome Analysis of *Saccharomyces Cerevisiae*. *Anal. Chem.* **2015**, *87* (10), 5387–5394. <https://doi.org/10.1021/acs.analchem.5b00708>.
- (97) Iguiniz, M.; Rouvière, F.; Corbel, E.; Roques, N.; Heinisch, S. Comprehensive Two Dimensional Liquid Chromatography as Analytical Strategy for Pharmaceutical Analysis. *J. Chromatogr. A* **2017**, 1–10. <https://doi.org/10.1016/j.chroma.2017.08.070>.
- (98) Iguiniz, M.; Corbel, E.; Roques, N.; Heinisch, S. Quantitative Aspects in On-Line Comprehensive Two-Dimensional Liquid Chromatography for Pharmaceutical Applications. *Talanta* **2019**, *195* (August 2018), 272–280. <https://doi.org/10.1016/j.talanta.2018.11.030>.
- (99) Iguiniz, M.; Heinisch, S. Two-Dimensional Liquid Chromatography in Pharmaceutical Analysis . Instrumental Aspects , Trends and Applications. *J. Pharm. Biomed. Anal.* **2017**, *145*, 482–503. <https://doi.org/10.1016/j.jpba.2017.07.009>.
- (100) Rainville, P. D.; Langridge, J. I.; Wrona, M. D.; Wilson, I. D.; Plumb, R. S. Integration of

Microfluidic LC with HRMS for the Analysis of Analytes in Biofluids: Past, Present and Future. *Bioanalysis* **2015**, *7* (11), 1397–1411. <https://doi.org/10.4155/bio.15.68>. View Article Online
DOI: 10.1039/C9AN02145K


- (101) Hendrickx, S.; Uğur, D. Y.; Yilmaz, I. T.; Şener, E.; Van Schepdael, A.; Adams, E.; Broeckhoven, K.; Cabooter, D. A Sensitive Capillary LC-UV Method for the Simultaneous Analysis of Olanzapine, Chlorpromazine and Their FMO-Mediated N-Oxidation Products in Brain Microdialysates. *Talanta* **2017**, *162*. <https://doi.org/10.1016/j.talanta.2016.09.053>.
- (102) Nys, G.; Fillet, M. Microfluidics Contribution to Pharmaceutical Sciences : From Drug Discovery to Post Marketing Product Management. *J. Pharm. Biomed. Anal.* **2018**, *159*, 348–362. <https://doi.org/10.1016/j.jpba.2018.07.011>.
- (103) Lotter, C.; Heiland, J. J.; Thurmann, S.; Mauritz, L.; Belder, D. HPLC-MS with Glass Chips Featuring Monolithically Integrated Electrospray Emitters of Different Geometries. *Anal. Chem.* **2016**, *88* (5), 2856–2863. <https://doi.org/10.1021/acs.analchem.5b04583>.
- (104) Rainville, P. D.; Murphy, J. P.; Tomany, M.; Wilson, I. D.; Smith, N. W.; Evans, C.; Kheler, J.; Bowen, C.; Plumb, R. S.; Nicholson, J. K. An Integrated Ceramic, Micro-Fluidic Device for the LC/MS/MS Analysis of Pharmaceuticals in Plasma. *Analyst* **2015**, *140* (16), 5546–5556. <https://doi.org/10.1039/C5AN00646E>.
- (105) Grinias, J. P.; Kennedy, R. T. Advances in and Prospects of Microchip Liquid Chromatography. *Trends Anal. Chem.* **2016**, *81*, 110–117. <https://doi.org/10.1016/j.trac.2015.08.002>.
- (106) Steuer, A. E.; Poetzsch, M.; Koenig, M.; Tingelhoff, E.; Staeheli, S. N.; Roemmelt, A. T.; Kraemer, T. Comparison of Conventional Liquid Chromatography – Tandem Mass Spectrometry versus Microflow Liquid Chromatography – Tandem Mass Spectrometry within the Framework of Full Method Validation for Simultaneous Quantification of 40 Antidepressants and Neurolept. *J. Chromatogr. A* **2015**, *1381*, 87–100. <https://doi.org/10.1016/j.chroma.2014.12.084>.
- (107) Jesionek, W.; Fornal, E.; Majer-Dziedzic, B.; Móricz, Á. M.; Nowicky, W.; Choma, I. M. Investigation of the Composition and Antibacterial Activity of Ukrain™ Drug Using Liquid Chromatography Techniques. *J. Chromatogr. A* **2016**, *1429*, 340–347. <https://doi.org/10.1016/j.chroma.2015.12.015>.
- (108) Bishop, D. P.; Blanes, L.; Wilson, A. B.; Wilbanks, T.; Killeen, K.; Grimm, R.; Wenzel, R.; Major, D.; Macka, M.; Clarke, D.; et al. Microfluidic High Performance Liquid Chromatography-Chip Hyphenation to Inductively Coupled Plasma–Mass Spectrometry. *J. Chromatogr. A* **2017**, *1497*, 64–69. <https://doi.org/10.1016/j.chroma.2017.03.025>.
- (109) Houbart, V.; Servais, A.; Charlier, T. D.; Pawluski, J. L.; Abts, F.; Fillet, M. A Validated Microfluidics-Based LC-Chip-MS / MS Method for the Quantitation of Fluoxetine and Norfluoxetine in Rat Serum. *Electrophoresis* **2012**, *33*, 3370–3379. <https://doi.org/10.1002/elps.201200168>.
- (110) Haghighi, F.; Talebpour, Z.; Sanati, A. Towards Fully Integrated Liquid Chromatography on a Chip : Evolution and Evaluation. *Trends Anal. Chem.* **2018**, *105*, 302–337. <https://doi.org/10.1016/j.trac.2018.05.002>.
- (111) Cappiello, A.; Famigliini, G.; Palma, P.; Truffelli, H. Matrix Effects in Liquid Chromatography-Mass Spectrometry. *J. Liq. Chromatogr. Relat. Technol.* **2010**, *33* (9–12), 1067–1081. <https://doi.org/10.1080/10826076.2010.484314>.
- (112) Shen, J. X.; Motyka, R. J.; Roach, J. P.; Hayes, R. N. Minimization of Ion Suppression in LC-MS/MS Analysis through the Application of Strong Cation Exchange Solid-Phase Extraction

- (SCX-SPE). *J. Pharm. Biomed. Anal.* **2005**, *37* (2), 359–367.
<https://doi.org/10.1016/j.jpba.2004.10.035>.
- (113) Wu, S. T.; Schoener, D.; Jemal, M. Plasma Phospholipids Implicated in the Matrix Effect Observed in Liquid Chromatography/Tandem Mass Spectrometry Bioanalysis: Evaluation of the Use of Colloidal Silica in Combination with Divalent or Trivalent Cations for the Selective Removal of Phospholipids. *Rapid Commun. Mass Spectrom.* **2008**, *22*, 2873–2881.
<https://doi.org/10.1002/rcm.3680>.
- (114) Yan, X.; Zhao, S.; Zhu, W.; Rao, J.; Xu, J.; Li, D.; Qin, L.; Qiu, L.; Li, G.; Huang, J.; et al. LC – MS / MS Assay of Ropinirole in Rat Biological Matrices : Elimination of Lysoglycerophosphocholines-Based Matrix Effect. *Bioanalysis* **2016**, *8* (17), 1823–1835. <https://doi.org/10.4155/bio-2016-0087>.
- (115) Koller, D.; Zubiaur, P.; Saiz-rodríguez, M.; Abad-santos, F.; Wojnicz, A. Simultaneous Determination of Six Antipsychotics , Two of Their Metabolites and Caffeine in Human Plasma by LC-MS MS Using a Phospholipid-Removal Microelution-Solid Phase Extraction Method for Sample Preparation. *Talanta* **2019**, *198*, 159–168.
<https://doi.org/10.1016/j.talanta.2019.01.112>.
- (116) Augusto, F.; Hantao, L. W.; Mogollo, N. G. S.; Braga, S. C. G. N. New Materials and Trends in Sorbents for Solid-Phase Extraction. *TrAC - Trends Anal. Chem.* **2013**, *43*, 14–23.
<https://doi.org/10.1016/j.trac.2012.08.012>.
- (117) Campiins-Falco, R.; Sevillano-Cabeza, A.; Herraéz-Hernandez, R.; Molins-Legua, C.; Moliner-Martinez, Y.; Verdu-Andrés, J. Solid-Phase Extraction and Clean-up Procedures in Pharmaceutical Analysis - Update Based on the Original Article by P. Campíns-Falcó, A. Sevillano-Cabeza, R. Herráez-Hernández, and C. Molins-Legua, Encyclopedia of Analytical Chemistry, © 2000, John Wiley. *Encyclopedia of Analytical Chemistry: Applications, Theory and Instrumentation*; John Wiley & Sons, 2012.
<https://doi.org/10.1002/9780470027318.a1920.pub2>.
- (118) Soichot, M.; Julliand, S.; Filatriau, J.; Hurbain, A.; Bourgogne, E.; Mihoubi, A.; Gurlain, H.; Toxicologie, S. De; Lariboisière, H.; Paré, R. A.; et al. Diagnosis of Heroin Overdose in an 8-Year-Old Boy : Reliable Contribution of Toxicological Investigations. *J. Anal. Toxicol.* **2018**, 255–264. <https://doi.org/10.1093/jat/bkx111>.
- (119) Stüber, M.; Reemtsma, T. Evaluation of Three Calibration Methods to Compensate Matrix Effects in Environmental Analysis with LC-ESI-MS. *Anal. Bioanal. Chem.* **2004**, *378* (4), 910–916. <https://doi.org/10.1007/s00216-003-2442-8>.
- (120) Nelis, M.; Augustijns, P.; Cabooter, D. Strategies for the Quantification of Endogenously Present Small Molecules in Biological Samples. *LC-GC Eur.* **2019**, *32* (7), 354–363.
- (121) Wang, J.; Gao, Y.; Dorshorst, D. W.; Cai, F.; Bremer, M.; Milanowski, D.; Staton, T. L.; Cape, S. S.; Dean, B.; Ding, X. Development of a Multi-Matrix LC–MS/MS Method for Urea Quantitation and Its Application in Human Respiratory Disease Studies. *J. Pharm. Biomed. Anal.* **2017**, *133*, 96–104. <https://doi.org/10.1016/j.jpba.2016.11.001>.
- (122) Toyo, T. LC – MS Determination of Bioactive Molecules Based upon Stable Isotope-Coded Derivatization Method. *J. Pharm. Biomed. Anal.* **2012**, *69*, 174–184.
<https://doi.org/10.1016/j.jpba.2012.04.018>.
- (123) Higashi, T.; Aiba, N.; Tanaka, T.; Yoshizawa, K.; Ogawa, S. Journal of Pharmaceutical and Biomedical Analysis Methods for Differential and Quantitative Analyses of Brain Neurosteroid Levels by LC / MS / MS with ESI-Enhancing and Isotope-Coded Derivatization. *J. Pharm.*

- Biomed. Anal.* **2016**, *117*, 155–162. <https://doi.org/10.1016/j.jpba.2015.08.040>. View Article Online
DOI: 10.1039/C9AN02145K
- (124) Kanu, A. B.; Dwivedi, P.; Tam, M.; Matz, L.; Hill, H. H. J. Ion Mobility – Mass Spectrometry. *J. Mass Spectrom.* **2008**, *43*, 1–22. <https://doi.org/10.1002/jms>.
- (125) Hernandez-Mesa, M.; Monteau, F.; Bizec, B. Le; Dervilly-pinel, G. Potential of Ion Mobility-Mass Spectrometry for Both Targeted and Non-Targeted Analysis of Phase II Steroid Metabolites in Urine. *Anal. Chim. Acta X* **2019**, *1*, 100006. <https://doi.org/10.1016/j.acax.2019.100006>.
- (126) Giusti, A.; Nguyen, X.; Kislyuk, S.; Mignot, M.; Croze, D.; Marc, L.; Ny, A.; Cabooter, D.; Witte, P. De. Safety Assessment of Compounds after In Vitro Metabolic Conversion Using Zebrafish Eleuthero Embryos. *Mol. Sci.* **2019**. <https://doi.org/10.3390/ijms20071712>.
- (127) Padilha, E. C.; Wang, J.; Kerns, E.; Lee, A.; Huang, W.; Jiang, J.; Mckew, J.; Mutlib, A.; Peccinini, R. G.; Yu, P. B.; et al. Application of in Vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). *Front. Pharmacol.* **2019**, *10*, 1–17. <https://doi.org/10.3389/fphar.2019.00234>.
- (128) Chavan, B. B.; Tiwari, S.; Shankar, G.; Nimbalkar, R. D.; Garg, P.; Srinivas, R.; Talluri, M. V. N. K. In Vitro and in Vivo Metabolic Investigation of the Palbociclib by UHPLC-Q-TOF / MS / MS and in Silico Toxicity Studies of Its Metabolites. *J. Pharm. Biomed. Anal.* **2018**, *157*, 59–74. <https://doi.org/10.1016/j.jpba.2018.05.008>.
- (129) Pierre, P. V.; Haglöf, J.; Linder, B.; Engskog, M. K. R.; Arvidsson, T.; Pettersson, C.; Fransson, A.; Laurell, G.; Videhult, P.; Haglöf, J.; et al. Cisplatin-Induced Metabolome Changes in Serum : An Experimental Approach to Identify Markers for Ototoxicity. **2017**, *6489* (August). <https://doi.org/10.1080/00016489.2017.1325006>.
- (130) Al-ghobashy, M. A.; Hassan, S. A.; Abdelaziz, D. H.; Elhosseiny, N. M.; Sabry, N. A.; Attia, A. S.; El-sayed, M. H. Development and Validation of LC – MS / MS Assay for the Simultaneous Determination of Methotrexate , 6-Mercaptopurine and Its Active Metabolite 6-Thioguanine in Plasma of Children with Acute Lymphoblastic Leukemia : Correlation with Genetic Polymorphism. *J. Chromatogr. B* **2016**, *1038*, 88–94. <https://doi.org/10.1016/j.jchromb.2016.10.035>.
- (131) Szultka-Młyńska, M.; Bajkacz, S.; Baranowska, I.; Buszewski, B. Structural Characterization of Electrochemically and in Vivo Generated Potential Metabolites of Selected Cardiovascular Drugs by EC-UHPLC/ESI- MS Using an Experimental Design Approach. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2018**, *176*, 262–276. <https://doi.org/10.1016/j.talanta.2017.08.041>.
- (132) Zawatzky, K.; Barhate, C. L.; Regalado, E. L.; Mann, B. F.; Marshall, N.; Moore, J. C.; Welch, C. J. Overcoming “ Speed Limits ” in High Throughput Chromatographic Analysis. *J. Chromatogr. A* **2017**, *1499*, 211–216. <https://doi.org/10.1016/j.chroma.2017.04.002>.
- (133) Schmitz, O. LC / MS Coupling. In *The HPLC Expert: Possibilities and Limitations of Modern High Performance Liquid Chromatography*; Kromidas, S., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA 2016, 2016; pp 1–60.
- (134) Couchman, L.; Fisher, D. S.; Subramaniam, K.; Handley, S. A.; Boughtflower, R. J.; Benton, C. M.; Flanagan, R. J. Ultra-Fast LC-MS/MS in Therapeutic Drug Monitoring: Quantification of Clozapine and Norclozapine in Human Plasma. *Drug Test. Anal.* **2017**, No. May, 1–7. <https://doi.org/10.1002/dta.2223>.
- (135) Hettiarachchi, K.; Hayes, M.; Desai, A. J.; Wang, J.; Ren, Z.; Greshock, T. J. Subminute Micro-Isolation of Pharmaceuticals with Ultra-High Pressure Liquid Chromatography. *J. Pharm.*

- Biomed. Anal.* **2019**, *176*, 112794. <https://doi.org/10.1016/j.jpba.2019.112794>. View Article Online
DOI: 10.1039/C9AN02145K
- (136) Xiang, P.; Yang, Y.; Zhao, Z.; Chen, M.; Liu, S. Ultrafast Gradient Separation with Narrow Open Tubular Liquid Chromatography. *Anal. Chem.* **2019**, *91*, 10738–10743. <https://doi.org/10.1021/acs.analchem.9b02190>.
- (137) Hussain, S.; Gosar, A.; Shaikh, T. Impurity Profiling in Pharmaceuticals: A Review. *World J. Pharm. Res.* **2018**, *7* (9), 305–320. <https://doi.org/10.20959/wjpr20189-12023>.
- (138) Services, H. *International Council for Harmonization. Guidance for Industry. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk (ICH M7/R1)*; 2018; Vol. 7.
- (139) Narayanam, M.; Handa, T.; Sharma, P.; Jhajra, S.; Muthe, P. K.; Dappili, P. K.; Shah, R. P.; Singh, S. Critical Practical Aspects in the Application of Liquid Chromatography – Mass Spectrometric Studies for the Characterization of Impurities and Degradation Products. *J. Pharm. Biomed. Anal.* **2014**, *87*, 191–217. <https://doi.org/10.1016/j.jpba.2013.04.027>.
- (140) Dousa, M.; Klvana, R.; Doubský, J.; Srbek, J.; Richter, J.; Exner, M.; Gibala, P. HILIC–MS Determination of Genotoxic Impurity of 2-Chloro-N-(2-Chloroethyl) Ethanamine in the Vortioxetine Manufacturing Process. *J. Chromatogr. Sci.* **2016**, *54* (2), 119–124. <https://doi.org/10.1093/chromsci/bmv107>.
- (141) Shelke, M.; Deshpande, S. S.; Sharma, S. Quinquennial Review of Progress in Degradation Studies and Impurity Profiling: An Instrumental Perspective Statistics Quinquennial Review of Progress in Degradation Studies and Impurity Profiling : An Instrumental Perspective Statistics. *Crit. Rev. Anal. Chem.* **2019**, *0* (0), 1–28. <https://doi.org/10.1080/10408347.2019.1615863>.
- (142) Guo, K.; Zhang, T.; Wang, Y.; Jin, B.; Ma, C. Characterization of Degradation Products and Process-Related Impurity of Sutezolid by Liquid Chromatography / Electrospray Ionization Tandem Mass Spectrometry. *J. Pharm. Biomed. Anal.* **2019**, *169*, 196–207. <https://doi.org/10.1016/j.jpba.2019.03.005>.
- (143) Guvvala, V.; Chidambaram, V.; Shree, J. A Study on Structural Characterization of Degradation Products of Cangrelor Using LC/QTOF/MS/MS and NMR. *J. Pharm. Biomed. Anal.* **2019**, *170*, 327–334. <https://doi.org/10.1016/j.jpba.2019.03.031>.
- (144) McBride, W. G. Thalidomide and Congenital Abnormalities. *Lancet* **1961**, *1358*, 291–293.
- (145) Nie, Y.; Liu, X.; Yang, X.; Zhao, Z. Review : Recent Application of Chiral Liquid Chromatography – Tandem Mass Spectrometric Methods for Enantiomeric Pharmaceutical and Biomedical Determinations. *J. Chromatogr. Sci.* **2013**, *51*, 753–763.
- (146) Ismail, O. H.; Felletti, S.; Luca, C. De; Pasti, L.; Marchetti, N.; Costa, V.; Gasparrini, F.; Cavazzini, A.; Catani, M. The Way to Ultrafast, High-Throughput Enantioseparations of Bioactive Compounds in Liquid and Supercritical Fluid Chromatography. *Molecules* **2018**, *23*, 2709. <https://doi.org/10.3390/molecules23102709>.
- (147) Hellinghausen, G.; Roy, D.; Lee, J. T.; Wang, Y.; Weatherly, C. A.; Lopez, D. A.; Nguyen, K. A.; Armstrong, J. D.; Armstrong, D. W. Effective Methodologies for Enantiomeric Separations of 150 Pharmacology and Toxicology Related 1°, 2°, and 3° Amines with Core-Shell Chiral Stationary Phases. *J. Pharm. Biomed. Anal.* **2018**, *155*, 70–81. <https://doi.org/10.1016/j.jpba.2018.03.032>.
- (148) Du, Y.; Luo, L.; Sun, S.; Jiang, Z.; Guo, X. Enantioselective Separation and Determination of Miconazole in Rat Plasma by Chiral LC – MS / MS : Application in a Stereoselective Pharmacokinetic Study. **2017**, No. 103. <https://doi.org/10.1007/s00216-017-0551-z>.

- 1
2
3 (149) Hasan, M.; Hofstetter, R.; Fassauer, G. M.; Link, A.; Siegmund, W.; Oswald, S. Quantitative View Article Online
DOI: 10.1039/C9AN02145K
4 Chiral and Achiral Determination of Ketamine and Its Metabolites by LC – MS / MS in Human
5 Serum , Urine and Fecal Samples. *J. Pharm. Biomed. Anal.* **2017**, *139*, 87–97.
6 <https://doi.org/10.1016/j.jpba.2017.02.035>.
7
8 (150) Guo, H.; Wahab, M. F.; Berthod, A.; Armstrong, D. W. Mass Spectrometry Detection of Basic
9 Drugs in Fast Chiral Analyses with Vancomycin Stationary Phases. *J. Pharm. Anal.* **2018**, *8* (5),
10 324–332. <https://doi.org/10.1016/j.jpha.2018.08.001>.
11
12 (151) Odoroki, K. T.; Udoh, Y. K.; Akamura, M. N.; Himizu, Y. S.; Asaki, T. S.; Tsuki, H. O.; Ada, K. W.;
13 In, J. Z. M.; Izuno, H. M.; Oshinari, K. Y.; et al. Sensitive and Comprehensive LC-MS/MS
14 Analyses of Chiral Pharmaceuticals and Their Hepatic Metabolites Using Ovomuroid Column.
15 *Anal. Sci.* **2018**, *34* (September), 1011–1015.
16
17 (152) Yoshinari, K.; Yamashita, K. Analytical Chemistry for ADMET Research: Recent Advances and
18 Future Directions in LC e MS/MS and Omics Approaches. *Drug Metab. Pharmacokinet.* **2016**,
19 *31* (1), 1–2. <https://doi.org/10.1016/j.dmpk.2015.12.006>.
20
21 (153) Ma, J.; Gao, Y.; Sun, Y.; Ding, D.; Zhang, Q.; Sun, B. Tissue Distribution and Dermal Drug
22 Determination of Indomethacin Transdermal-Absorption Patches. **2017**, 617–624.
23 <https://doi.org/10.1007/s13346-017-0392-5>.
24
25 (154) Wang, Y.; Zhao, L.; Li, T.; Yang, W.; Li, Q.; Sun, L.; Ding, L. Pharmacokinetics and Tissue
26 Distribution Study of Clevidipine and Its Primary Metabolite H152/81 in Rats. *Biomed.*
27 *Chromatogr.* **2017**, No. July, 1–11. <https://doi.org/10.1002/bmc.4048>.
28
29 (155) Kucwaj-Brysz, K.; Kurczab, R.; Żesławska, E.; Lubeska, A.; Anna Marc, M.; Latacz, G.; Satala, G.;
30 Nitek, W.; Kieć-Kononowicz, K.; Handzlik, J. The Role of Aryl-Topology in Balancing between
31 Selective and Dual 5-HT₇R/5-HT_{1A} Actions of 3,5-Substituted Hydantoins. *Med. Chem.*
32 *Commun.* **2018**, *9*, 1033–1044. <https://doi.org/10.1039/c8md00168e>.
33
34 (156) Tanner, L.; Haynes, R. K.; Wiesner, L. An in Vitro ADME and in Vivo Pharmacokinetic Study of
35 Novel TB-Active Decoquinone Derivatives. *Front. Pharmacol.* **2019**, *10* (February), 1–10.
36 <https://doi.org/10.3389/fphar.2019.00120>.
37
38 (157) Bu, X.; Regalado, E. L.; Hamilton, S. E.; Welch, C. J. The Emergence of Low-Cost Compact Mass
39 Spectrometry Detectors for Chromatographic Analysis. *TrAC - Trends Anal. Chem.* **2016**, *82*,
40 22–34. <https://doi.org/10.1016/j.trac.2016.04.025>.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



b)




Figure 1: **a)** Detailed scheme of the LEI interface. Reproduced from ref. 31 with permission from Elsevier, copyright 2019. **b)** Scheme of the vaporization chamber in the optimized SMB LC-EI MS system. Reproduced from ref. 33 with permission from John Wiley & Sons, Ltd., copyright 2015.




Figure 2: High-throughput analysis of a 96-well plate (highlighting the injection of well E11) monitored by UHPLC-QDa MS. The incomplete conversion of the starting material ($[M+H]^+ = 143$ amu) to the desired product ($m/z = 223$ amu) is shown, while the presence of a reaction byproduct ($m/z = 299$ amu) is also indicated. Reproduced from ref. 38 with permission from Elsevier, copyright 2016.




Figure 3: Calibration curves of sunitinib spiked in plasma extracts, from LC-ESI⁺-MS analyses performed with a QQQ-MS (A) and HRMS (B) acquiring SRM and HR-FS acquisitions, respectively. Chromatograms (on the left-hand side) show sunitinib at the LOD level (0.0125 ng/mL). Truncated peak shape found at high concentrations on the QQQ-MS indicates a saturation of the detector. Reproduced from ref. 43 with permission from Elsevier, copyright 2016.




Figure 4: A generic scheme of how analytes are isolated, fragmented and analyzed by a mass spectrometer working in multiple reaction monitoring (MRM), parallel reaction monitoring (PRM), data-dependent acquisition (DDA), or data-independent acquisition (DIA) modes. Reproduced and adapted from ref. 52, F1000research (open access), copyright 2016.




Figure 5. Overlaid 2D separations of 1D fractions, indicated by blue areas. **(a)** UV detection and **(b)** MS-TIC detection signal. Circled compounds are detected in MS but not in UV. Reproduced from ref. 97 with permission from Elsevier, copyright 2017.




Figure 6. Schematic drawings (top row) and SEM images (bottom row) of different emitter geometries. The elution channel is depicted about three times bigger than in the actual chip. The SEM image of the pulled emitter shows the emitter in a side view with removed cover glass slide, revealing the tapered etched channel. The other geometries are shown in frontal view. Reproduced from ref. 103 with permission from the American Chemical Society, copyright 2016.




Figure 7. MISER analysis to support high throughput screening of ketoreductase variants produced by site saturation mutagenesis. **a)** Reaction scheme highlighting the desired oxidation of the alcohol (4) to the desired ketone (5). **b)** MISER analysis of product formation enables analysis of 96 reactions in 17 min. Reproduced from ref. 132 with permission from Elsevier, copyright 2017.